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INTRODUCTION 
Health is multifactorial and multidimensional, influenced by various factors. 
Disease is generally an individual problem and infirmity is probably a result of 
genetic makeup and environmental influences. Several disorders that affect the oral 
mucosal health are acquired through various lifestyle practices. Addictions for any 
adverse habit merely represent man’s unbounded weakness. Such adverse habits may 
follow the ladders of culture or mere addiction; which forms a platform for disease to 
show its synchronous presence. In day to day clinical practice Dentists often 
encounter a wide spectrum of oral mucosal alterations. These mucosal alterations 
may be in the form of changes in the colour, size, shape and texture. They range from 
innocuous mucosal alterations needing simple therapeutic remedies to more 
interventional procedures. Many of these lesions are caused by habit of betel nut and 
tobacco use. Oral Submucous Fibrosis (OSMF) is one among them which is 
frequently encountered due to betel nut chewing. 
  Schwartz in 1952 described a condition affecting the oral mucosa including 
the palate and faucial pillar, called "atrophia idiopathica (tropica) mucosae oris" 
among five Indian women from Kenya
1
.  Later the term “Oral submucous fibrosis” 
was coined by S.G Joshi in 1953
2
. It was also called by the other names like 
"idiopathic scleroderma of the mouth", "idiopathic palatal fibrosis", "juxta-epithelial 
fibrosis". Paymaster (1956) observed the precancerous nature of OSMF, because of 
the slow onset of squamous cell carcinoma in one third of OSMF patients
3
. 
In 1966 Pindborg and Sirsat, defined OSMF as “an insidious, chronic 
disease affecting any part of the oral cavity and sometimes the pharynx. Although 
occasionally preceded by and/or associated with vesicle formation, it is always 
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associated with juxta-epithelial inflammatory reaction followed by fibroelastic 
change of the lamina propria, with epithelial atrophy leading to stiffness of the oral 
mucosa and causing trismus and inability to eat”4. 
The disease is predominantly seen in India among Asian countries, with a 
reported prevalence ranging up to 0.4% in Indian rural population. Based on study 
conducted in 2002, more than 5 million people in India  suffer from OSMF (0.5 % of 
Indian population). OSMF is widely prevalent in all age groups and across all 
socioeconomic strata in India
5
.   
Several factors play a role in the etiopathogenesis of OSMF and current 
evidence suggests that arecoline in the areca nut is the key factor in initiating the 
disease
6
.
 
The habit of betel quid chewing is widespread throughout India and South 
East Asia. And it is widely prevalent in teenagers and young adults
7
.
 
Buccal mucosa, faucial pillar, soft palate are predominantly affected. 
Underlying muscles and the muscles of mastication can also be involved. The 
mucosa in the involved areas gradually becomes pale followed by progressive 
stiffness of subepithelial tissues. Increased incidence of malignancy is noted in 
OSMF patients which is around 8% in overall affected Indian population
8
.  
Many treatment protocols have been proposed for OSMF to alleviate the 
signs and symptoms which include intralesional steroids, hyaluronidase, placentrax, 
immunomodulatory drugs, immunised cow milk
9
, colchicine
10
, antioxidant, 
nutritional supplements, physiotherapy, combined medical therapy and surgical 
therapy with varying degrees of benefits
11
. But none of them proved to be effective 
due to their own short comings.  
Currently pentoxifylline, tri-substituted methylxanthine derivative, is reported 
to have satisfactory result in the management of OSMF due to their immune 
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modulation, alteration of fibroblast physiology, rheologic modification and anti-
inflammatory property. Immunologic abnormalities have been primarily reported 
with OSMF which probably mediate local tissue damage and that they appear to be 
the final common pathway in the pathogenesis of OSMF. Pentoxifylline has 
immunomodulating effects which include increasing leucocyte adhesion, causing 
neutrophil degranulation and release of peroxides and decreasing production of 
tumour necrosis factor alpha
12
. The review of current literature shows that the use of 
pentoxifylline in OSMF management has not been adequately explored and research 
in this area is very limited. Very few studies have been done so far, that too mainly 
involve subjective evaluation like mouth opening, blanching of oral mucosa, burning 
sensation. Objective evaluation of treatment outcome in OSMF patient can be carried 
out using ultrasonography. 
Ultrasonographic(USG) imaging is considered as a “real-time” imaging, 
which generate electrical impulses that are converted into high frequency sound 
waves by a transducer and transmitted into the tissues being examined. It is then 
reflected as echoes and reconverted into electrical energy, amplified, processed, and 
displayed on the monitor
13
.  USG is particularly suitable for imaging superficial 
structures of the oral mucosa and  provides both quantitative and qualitative 
assessment, the nature and dimension of lesion or structure
14
. 
The purpose of the study is to evaluate objectively the effectiveness of oral 
pentoxifylline for the treatment of OSMF using high frequency ultrasonography in 
comparision to conventiontal intralesional steroid therapy with dexamethasone and 
hyaluronidase.            
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AIM AND OBJECTIVE 
AIM: 
To evaluate the therapeutic efficacy of Oral Pentoxifylline in treatment of 
oral submucous fibrosis patients using ultrasonography. 
 
OBJECTIVE: 
1. To assess the clinical symptoms like burning sensation, mouth Opening, 
both preoperatively and postoperatively. 
2. To measure the Sub mucosal layer thickness in oral submucous fibrosis  
patients, pre and post treatment using ultrasonography 
3. To assess the Echogenecity of buccal mucosa in oral submucous fibrosis  
patients, pre and post treatment using ultrasonography 
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REVIEW OF LITERATURE 
HISTORY 
OSMF has been well established in Indian medical literature since the time of 
Susrutha, a renowned Indian physician, who described a condition resembling 
OSMF as Vidari under mouth and throat during the period of 2500-3000 BC. He 
noted pain on taking spicy food, depigmentation of oral mucosa and progressive 
narrowing of oral cavity
4
. 
Schwartz (1952)
1
 for the first time reported a case of “Atrophia Idiopathica 
tropica mucosae oris” occurring in Indians in East Africa and described blanching 
and stiffness of the oral mucosa, difficulty in opening the mouth and inability to 
tolerate spicy food. 
           Sirsat  (1962)
15
 an ENT surgeon from India first described this condition and 
coined the term “submucous fibrosis of palate and pillar of fauces”. Rao (1962)16 
observed the fibrous bands extending to the lateral wall of pharynx via the faucial 
pillars down to the pyriform fossa. 
Pindborg and sirsat (1964)
17
 coined the term Oral Submucous fibrosis. 
Pindborg JJ et al (1965) studied the frequency of oral submucous fibrosis among 10 
south Indians with oral cancer. Forty of the 10 oral cancer patients had clinical signs 
of submucous fibrosis. 
Mathew B et al (1967)
18
 reported oesophageal involvement in 5 of 11 OSMF 
patients. 
EPIDEMIOLOGY: 
  Pindborg JJ et al (1968)
5
 in their epidemiological survey concluded that 
there is an increased incidence of OSMF of about 0.18%-1.2% in urban population 
when compared with 0.04% - 0.4% in rural population. 
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Ranganathan K et al (2004)
19
 conducted a study in Chennai, South India, 
reported a mean age of 32.4±10.4 years and median age of 29 years. The youngest 
and oldest ages of occurrence of OSMF in this study was 16 and 76 years in males 
and 24 and 57 years in females. Occurrence of the disease in individuals as young as 
2, 3.5, 4, 11 and 12 years has also been reported. 
ETIOLOGY: 
  Wahi PN et al (1966)
20
 in their study reported OSMF to be higher in patients 
with poor nutritional status. They found that the patients with OSMF showed a 
higher frequency of deficiency of vitamin A, B, C and multiple vitamin. 
Gupta PC et al (1966)
21
 stated that oral use of any tobacco product like 
gutkha contain arecanut and several other substances in powdered or granulated form 
which causes oral submucous fibrosis 
Phatak AG (1978)
22
 did a study on 34 patients suffering from OSMF and 
observed that these patients had significantly elevated levels of serum globulin and 
immunoglobulin IgG, stating the possibility of OSMF being an auto-immune 
disorder. 
  Canniff JP et al (1986)
11
 suggested that the addition of slaked lime to areca 
nut hydrolyses arecoline to arecaidine which means that the hydrolysis of arecoline 
could occur in the saliva as well as in fibroblasts. It was also suggested that the 
inflamed mucosa had enhanced permeability to arecoline and arecaidine. 
Van wyk CW et al (1988)
23
 have reported about irreversibility nature of the 
disease i.e., once OSMF induced by the habit of chewing betel nut, the reversal of the 
disease after cessation of the habit could not occur. 
  Sinor PN et al (1990)
24
 demonstrated the Dose-response relationship – the 
relationship between degree of exposure and the risk of a disease is an important 
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criterion for causal inference. In a case-control study from India, the relative risk 
increased with the duration as well as the frequency of the areca nut chewing habit. 
In a bivariate analysis of the duration and frequency of the habit, the risk of OSMF 
showed a clear dose-response relationship 
Jeng JH (1994)
25
 conducted a study to observe the pathobiological effects of 
aqueous extracts of three betel quid constituents, inflorescence of piper betel, 
arecoline and catechin on cultured oral mucosal fibroblasts. Result showed that betel 
quid contained not only genotoxic and cytotoxic agents but also compounds that had 
the ability to stimulate cellular proliferation  
Murti PR et al (1995)
7
 found on their tissue culture experiments using 
human fibroblasts and suggested that arecanut alkaloids yield powerful carcinogenic 
nitrosamines which explains the malignant potential of OSMF. 
Trivedy C et al (1999)
26
 in their study observed that copper is released from 
areca products during chewing and is deposited in oral tissues. They found that 
lysyloxidase activity is upregulated in OSMF patients.From these findings they 
hypothesized that cellular events lead to cross linking of collagen and elastin, making 
them less degradable. The upregulation of lysyloxidase in OSMF may be an 
important factor in the pathogenesis of this disorder. 
Chen HM (2004)
27
 conducted study on HLA typing in Taiwanese patients 
and found significantly greater phenotype frequency of HLA-B76 and haplotype 
frequencies of HLA-B48/Cw7, B51/Cw7 and B62/Cw7 in OSMF patients than in 
healthy control subjects. These findings suggested that some Taiwanese areca quid 
chewers with specific HLA phenotypes or haplotypes are prone to have OSMF 
Tu HF et al (2006)
28
 conducted on the functional polymorphisms of matrix 
metalloproteinase 3 gene among male OSMF patients using areca, reported that the 
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5A genotype in MMP3 promoter was observed more frequently in OSMF patients 
than in controls. The results indicated that the 5A genotype of MMP3 promoter was 
associated with the risk of OSF 
CLINICAL SYMPTOMS  
Rao AB (1962)
16
 noted features like inability to open mouth and intolerance 
to hot spicy food in 35 of 46 patients in his study, 3of 46 patients could not blow out 
a candle and had inability to protrude their tongue, 15 of 46 patients complained of 
pain in the ear and 6 of 46 patients complained of swelling and pain around the lower 
jaw and neck 
Pindborg JJ and Sirsat (1966)
4
 in their article noted prodromal symptoms 
like burning sensation for spicy food, blisters and ulceration or recurrent stomatitis,  
defective gustatory sensation, excessive salivation and dryness of mouth on OSMF 
patients. 
  Phookan J et al (1998)
29
 studied 32 patients with different oral lesions over 
the time span of one year and found incidence of OSMF to be 0.2%. Buccal mucosa 
was the common site of involvement, and white discoloration of mucosa was the 
common presenting symptom. All the cases in the study were found to be associated 
with betel nut chewing habit. 
Sumeth Perera MWD et al (2007)
30
 in their studies on the areca nut-treated 
oral epithelium showed progressive changes in epithelial thickness leading to 
epithelial atrophy, fibrosis of connective tissue with increased cellularity,  focal 
inflammatory cells infiltrate and muscle atrophy. This study concluded that evidence 
of areca nut contribution to the development of OSMF in treated animals has been 
elucidated. 
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  Reichart et al (1984)
31
 studied 15 biopsies of oral mucosa of betel chewers 
who were studied histologically and by transmission electron microscopy (TEM) and 
scanning electron microscopy (SEM). Histologically marked reduction of retepegs, 
epithelial atrophy, hyper ortho or parakeratosis, sub-epithelial edema and 
inflammatory infiltrate were the prominent findings 
  El Labbon et al (1985)
32
 have investigated the muscle changes 
ultrastructurally in  OSMF patients and concluded that restricted mouth opening in 
OSMF might be depend upon not only on subepithelial fibrosis, but also on the 
extent of degeneration of masticatory muscle.  
Reichart PA et al (1994)
31
 concluded in their study that the process of 
fibrosis starts in the deeper subepithelial connective tissue stroma and not close to the 
subepithelial basement membrane.  
Cox SC and Walker DM (1996)
33
 in their review article stated that the 
retromolar areas and the buccal mucosa were commonly involved, followed by soft 
palate, palatal fauces, uvula, tongue and labial mucosa. The main diagnostic criteria 
for OSMF clinically was the presence of fibrous bands either in the buccal or  labial 
mucosa and in the posterior part of palate. 
Tilakarathne WM et al (2006)
34
 reviewed about the disease progression and 
sequential disabilities of oral functions like restricted mouth opening, inability to 
blow out a candle or whistle and difficulty in swallowing. They concluded that bands 
are common at the back of the mouth in mild cases of OSMF and as the disease 
increases in severity are more likely to be found anteriorly as well.  
 
 
 
                                                                   Review Of Literature 
 
10 
 
 
PRECANCEROUS POTENTIAL: 
         Paymaster JC (1956)
3
 was the first to mention submucous fibrosis as a 
premalignant condition. He reported slow growing of squamous cell carcinoma in 
1/3rdof his patients with OSMF. 
Pindborg JJ (1972)
35
 summarized a criteria to support the precancerous 
nature of this disease as 
 Higher prevalence of leukoplakia among OSMF patients.  
 Higher frequency of epithelial dysplasia.  
 Concurrent findings of OSMF in oral cancer patients. 
 Histopathological diagnosis of oral cancer without clinical suspicion among 
OSMF cases. 
 Higher rate of incidence of oral cancer among patients with OSMF 
Murti PR et al (1985)
8
 proposed that the malignant transformation rate has 
been reported to be 4.5% over a 15 year period. With the further follow up for 
another two years showed that the rate of malignant transformation arose to 7.6%. 
Oral cancer developed 3-16 years after the diagnosis of submucous fibrosis. The 
average age at the time of malignant transformation was 64.6 years and age range 
was 48-81 years. 
 Dave et al (1991)
36
 reported a statistically significant increase in the size C-
band heteromorphism patterns on chromosome 1 in submucous fibrosis and oral 
squamous cell carcinoma patients when compared with healthy subjects. In another 
cytogenetic study by the same author, an increase in the frequency of sister-
chromatid exchanges and chromosome aberrations in areca nut consumers with 
OSMF and OSCC was noted. 
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TREATMENT MODALITIES: 
Sinha and Jain (1978)
37
 have tried multiple submucosal injection of 1.5 cc 
hydrocortisone in OSMF patients and found to be effective in controlling symptoms 
and alleviating inflammatory findings. 
Kakar PK et al (1985)
38
 observed in a group of 96 patient who received 4 
regimens of treatment which were intralesional dexamethasone or hyaluronidase, 
combination of dexamethasone and hyaluronidase and local placental extract. The 
group of patients receiving hyaluronidase alone showed faster improvements in 
symptoms. However combination with dexamethasone gave better longer term 
results. 
 Gupta et al (1988)
39
 reported successful treatment of OSMF with local 
injection of chymotrypsin, hyaluronidase and dexamethasone. 
   Borle et al (1991)
40
 concluded from his studies that all available treatment 
for OSMF are basically palliative in nature and provide only symptomatic relief and 
retard the manifestations of the disease. They also suggested that conservative 
treatment is safer and less hazardous than treatment with submucosal injections. 
 Dinesh CG et al (1992)
41
 suggested that no one treatment modality is 
successful in completely eliminating the disease. In patient with grade III and grade 
IV injectable corticosteroids or hyaluronidase locally is helpful and to prevent 
relapse placentrex and ranindone combination is advised. 
PENTOXIFYLLINE: 
Occlusive blood vessels encountered in OSMF restrict nutrients and 
therapeutic substances from reaching the affected tissue, which may be one of the 
reasons for the unsatisfactory therapeutic effect of local medical treatment. Thus 
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drug with vasoaltering property were started using in the management of OSMF. 
Lai et al (1995)
42
 has tried management of OSMF using buflomedial HCL (3 
tablets of 45mg per day) and topical trimacenolone acetonide 0.1% ointment on 
mucosal ulcers at bed time. He observed better results. Buflomedial HCL (peripheral 
vasodialator) has been found to improve the the tissues with diffuse fibrosis to a 
noticeable degree by the relief of local ischemic effect. 
Recently Pentoxifylline, a methylxanthine derivative has been found to exert 
fibrinolytic effect on cultured fibroblasts or animal models of fibrosis, including liver 
fibrosis. In hepatic stellate cell culture, Pentoxifylline has been shown to inhibit liver 
fibrogenesis. 
Rajendran et al (2006)
43
 used pentoxifylline which has rheologic modifying  
properties. It was administered as 400mg thrice daily for a period of more than 12 
months and observed improvement in symptoms of OSMF. 
Mehrotra et al (2011)
44
 studied the effectiveness of pentoxifylline in 29 
cases of OSMF for a period of 7 months and concluded that it has found to be 
effective in alleviating the symptoms and can be used as adjuvant in the management 
of OSMF. 
Anjum Aara et al (2012)
45
 studied clinically to evaluate the efficacy of oral 
Pentoxifylline 400mg in  OSMF patients in comparison to intralesional injections of 
Dexamethasone (4mg/ml) and Hyaluronidase 1500 IU in the management of OSMF 
patients.  He concluded that Pentoxifylline can be safer and better alternative in the 
treatment of oral submucous fibrosis in comparision to dexamethasone. 
Various method have been employed to evaluate the outcome of medical 
management of OSMF which were mainly subjective, like alleviation of symptoms 
like burning sensation, alteration in texture of mucosa, changes in blanching of 
                                                                   Review Of Literature 
 
13 
 
 
mucosa and improvement in mouth opening. Ultrasonography proved to be effective 
in evaluating the progression and treatment outcome in course of time. It is non 
invasive, real time imaging modality helpful in identifying the distribution of fibrosis 
and submucosal changes with medicinal therapy. 
ULTRASONOGRAPHIC EVALUATION: 
Professor Ian Donald
46
 of Glasgow is credited with being the first to 
successfully use diagnostic ultrasonography to investigate the gravid uterus and is 
considered as the father of modern ultrasonography. 
The echogenecity of a tissue primarily relates to its stiffness, the chief source 
of which is collagen, the content and arrangement of collagen with in tissue is a 
major factor in modification of the manner and extent to which a tissue attenuates the 
acoustic wave. The applications of USG in head and neck region is for examination 
of the thyroid gland, the salivary gland, the eye, examination of fetal face and 
sonically guided surgery. 
Ian R Wilson (1989)
14
 concluded that USG imaging of the superficial 
structures of the head and neck region plays a significant part in the investigation of 
virtually all non acute superficial swelling and mass lesions. USG have got added 
advantage of enabling clearer definition of the tissues of the head and neck, better 
documentation of the range of clinical application, assessment of the accuracy of 
USG in predicting subsequent histopathologic findings. They have recommended 
that USG should be a part of the diagnostic equipment used in oral radiology. 
Jackowski J et al (1999)
47
 compare the ultrasonographic (USG) appearances 
of the oral mucosa in health with systemic sclerosis and concluded that 2MHz 
sonography may be suitable as a non-invasive tool for evaluation of fibrosis of the 
oral mucosa. 
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Müller et al (1999)
48
 conducted a clinical study in 33 patients to measure 
gingival thickness by means of USG. The transducer probe 4 mm in diameter was 
applied at the midfacial sites of each tooth, with light pressure to produce acoustic 
coupling. The result concluded that USG was demonstrated to be useful for gingival 
thickness measurement. 
A study was attempted to investigate the reproducibility of the pulsed 
ultrasound technique for the determination of skin thickness using two independent 
observers. Studies were undertaken to validate the pulsed ultrasound technique as a 
measure of true skin thickness. Skin thickness was determined invitro (histometric 
analysis) was found to be greater than invivo (ultrasound) determination, probably 
due to release of invivo tension within the dermis after excision. 
Kiliardis et al (2007)
49
 studied the bilateral differences in the thickness of 
the masseter muscles in untreated individuals with lateral crossbite, as well as in 
subjects with successfully treated functional lateral crossbite, at least three years after 
the end of treatment. He reported that USG imaging has also been shown to be a 
useful tool to measure muscles thickness.  
Serra et al (2008)
50
 discussed the advantages and disadvantages of using 
ultrasonography to assess the masticatory muscles. The authors reported that there 
were different techniques available for recording the thickness of the muscles, and 
that the ultrasound technique generally showed lower reproducibility in relaxed than 
in contracted muscles. The authors suggested that ultrasound should be preferred in 
comparison with CT and magnetic resonance imaging due to its safety and cost 
advantages, since it is as reliable and precise as those techniques 
Wakasugi-Sato et al (2010)
51
 demonstrated the clinical applications of 
ultrasound imaging in soft tissue lesions, guided fine-needle aspiration, measurement 
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of tongue cancer thickness, and diagnosis of metastasis to cervical lymph nodes. The 
Doppler mode in ultrasound was reported to be a useful modality in the differential 
diagnosis between normal and metastatic lymph nodes in patients with oral 
squamous cell carcinoma. 
  Rangaiah et al (2010)
52
 aimed to measure submucosal thickness by high 
frequency USG in cases and controls, to correlate this with clinical and histological 
severity of the OSMF. Cases had increased submucosal thickness when compared to 
controls at all measured sites. The echogenicity pattern of cases showed areas of 
irregular hyperechoic linear streaks due to fibrotic submucosal deposit.  In contrast, 
the submucosa of controls appeared as a hypoechoic band.  
Manjunath et al (2011)
53
 conducted study to evaluate oral submucous 
fibrosis (OSMF) by clinical and histopathological examination, and compare the 
results with those from ultrasonographic technique. USG demonstrated number, 
length and thickness of the fibrotic bands. It helps in alteration of the treatment 
schedule in selected cases and allows for post treatment follow-ups and assessment. 
 So, it could be a better diagnostic tool compared to clinical and histopathological 
examination. 
Devathambi et al (2013)
54
 evaluate the efficacy of USG in assessing the 
severity of OSMF and also to assess the relationship between OSMF and 
hypertrophy of massetter muscle. He concluded that USG is an effective non 
invasive tool to assess the progression of OSMF. 
Krithika et al (2013)
55
 characterize the ultrasonographic features of the 
buccal mucosa in patients with oral submucous fibrosis. Ultrasonography of the 
buccal mucosa demonstrates increased submucosal echogenicity and reduced echo 
differentiation between submucosa and muscle layer in OSMF cases. Hence, it can 
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be used as a non-invasive imaging modality to assess the disease extent and severity 
across the entire buccal mucosa to supplement clinical evaluation.  
 Joshi et al (2014)
56
  reported that USG is easy to-use for the detection of 
non-invasive and soft tissue related diseases in oral and maxillofacial regions. USG 
plays an important role in analyzing normal and abnormal structures. In particular, in 
oral and maxillofacial regions, the USG may be clinically applied to evaluate lymph 
nodes, subcutaneous, and oral cavity-related diseases 
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PATHOGENESIS OF OSMF 
Different hypotheses have been put forward so far in fully elucidating the 
pathogenisis of OSMF. The betel quid (BQ) chewing has been recognized as one of 
the important risk factors for OSMF as supported by the various experimental 
studies. The alkaloids and flavonoids from the BQ are absorbed and undergo 
metabolism which are the constant source of irritation to the oral mucosa during their 
contact. In addition, the fibres of areca nut also cause mechanical irritation to the oral 
mucosa which facilitates the diffusion of alkaloids and flavanoids into the 
subepithelial connective tissue, resulting in juxtaepithelial inflammatory cell 
infiltration
57
. 
 Inflammation is characterized by the presence of activated T cells, 
macrophages and various chemical mediators. Persistent inflammation is crucial for 
the occurrence of tissue fibrosis. Thus, it can be considered that the induction of oral 
mucosal inflammation by BQ ingredients to be a critical event in the pathogenesis. 
    Growth factors like transforming growth factor- β (TGF-β) are synthesized 
at the sites of inflammation. At the molecular level, the collagen production and 
degradation are regulated by TGF-β and flavonoids present in areca nut58. 
Collagen production pathway: 
          The three main events which favours the collagen production are  
1. Activation of procollagen genes 
2. Elevation of procollagen proteinases levels 
3. Upregulation of lysyl oxidase (LOX) activity 
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  TGF-β activates the procollagen genes, resulting in the production of more 
pro-collagen. In OSMF, there is increased cross-linking of the collagen, resulting in 
increased insoluble form of collagen. The flavanoids also increase cross-linking in 
the collagen fibers.This is facilitated by increased activity and production of a key 
enzyme – LOX, which  result in increased collagen production59. 
Collagen degradation pathway: 
  There are two main events regulated by TGF-β which decreases collagen 
degradation  
1. Activation of tissue inhibitor of matrix metalloproteinases gene (TIMPs). 
2. Activation of plasminogen activator inhibitor (PAI) gene. 
         TGF-β activates genes for TIMPs which inhibits the activated collagenase 
enzyme that is necessary for degradation of collagen. It also activates the gene for 
PAI, which is an inhibitor of plasminogen activator, results in absence of active 
collagenase. The flavanoids inhibit the collagenase activity. A reduction in the 
activity and levels of collagenase results in a decrease in collagen degradation
60
.
 
        Lysyl oxidase (LOX) is a copper activated enzyme critical for collagen cross-
linking and organization of extracellular matrix (ECM), which has been shown to be 
ten times more resistant to digestion by collagenase. A study was conducted to 
compare the LOX activity of fibroblasts derived from human normal mucosa and 
OSMF associated with betel nut chewing. The study revealed that OSMF fibroblasts 
showed reasonably more lysyl oxidase activity than normal mucosa fibroblasts and 
this was statistically significant (p<0.05)
61
.
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        Copper also has been implicated in the pathogenesis of OSMF. Areca nut has 
been found to have a high copper content and play an important role in the 
pathogenesis of OSMF. The possible role of copper functioning as a mediator of 
fibrosis in OSMF has been proved by the finding that raised copper levels in oral 
biopsies from patients with OSMF
62
. 
        Plasminogen/plasmin system plays an important role in maintaining the 
equilibrium between synthesis and degradation of extracellular matrix (ECM). 
Plasminogen Activation inhibitor(PAI-1) inactivtes the plasminogen activators 
resulting in a decreased production of plasmin which is required for the degradation 
of ECM. Hence increased concentrations of PAI-1 leads to an accumulation of 
ECM
63
. 
         OSMF is characterized by qualitative and quantitative alteration of collagen 
within the subepithelial layer of oral mucosa. The degradation of collagen by 
fibroblast phagocytosis is an important physiological remodeling of connective 
tissue. OSMF tissues exhibited 40% reduction of collagen phagocytic cells and a 
48% decrease of fibronectin phagocytic cells as compared to normal fibroblasts. 
Normal fibroblast cultures incubated with areca nut alkaloids provided a dose-
dependent reduction in the proportions of phagocytic cells. Thus inhibition of 
fibroblast phagocytosis by alkaloids  provide a mechanism for the development of 
OSMF
64
. 
         Further persistent tissue inflammation is thought to play a vital role on the 
occurrence of tissue fibrosis. The induction of oral mucosal inflammation by 
arecoline may be critical in the pathogenesis of OSMF. A study was conducted to 
compare role Cyclooxygenase (COX)-2 expression in normal buccal mucosa and 
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OSMF patients. The study found that COX-2 expression was significantly higher in 
OSMF specimens compared to normal buccal mucosa, however when the cells were 
treated with 80 μg/ml arecoline, COX-2 expression was upregulated in normal 
mucosa. These results concluded that the upregulation of COX-2 expression in 
human buccal mucosal fibroblasts could play a vital role in the pathogenesis of 
OSMF
65
.
 
 Cytokines play an important role in regulating proliferation, migration and 
matrix synthesis of fibroblast and it is the balance of these mediators which play a 
key role in regulating the initiation and progression of any fibrotic disease. TNF-α, 
IL-1, IL-6 and IL-8 have been implicated in the development of fibrosis. Conversely, 
IFN-γ is an antifibrotic cytokine and downregulation of which is seen in keloid and 
scleroderma patients
66
. 
 A hypothesis that is commonly reported in OSMF patients is the epithelial 
alteration. The epithelium is considered to be “atrophic” and therefore vulnerable to 
the effects of oral carcinogens. “Atrophy” is explained to be arise as a result of 
stromal changes, which include decrease in cellularity and vascularity with resultant 
tissue ischemia and  undergoes progressive hyalinization
67
.  
   However the epithelium in OSMF failed to demonstrate an increased 
Absolute Cell Death Index (ACI) often seen in tissue atrophy.  An alternative 
hypothesis was proposed which state that  hypoproliferation of epithelium was a 
factor which causes thinning of surface epithelium rather than atrophy in advanced 
cases of OSMF
68
. 
           Recent study with regard to vascularity in OSMF was conducted to assess the 
degree of expression of nitric oxide (NO), a net vasodilator, in OSMF. The study 
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concluded that enhanced expression of inducible nitric oxide synthase (iNOS) 
noticed in OSMF mucosa. NO has diverse properties of angiogenesis, vascular 
dilatation and increased permeability of vessels. These properties are all contrary to 
the concept of tissue hypoxia in OSMF and therefore the proposed “ischemic 
atrophy” of the overlying epithelium. This augments the earlier contention of an 
alternative explanation for thinning of the epithelium often noticed in clinically 
advanced cases. The thinning may be attributed to the defective replenishment of the 
desquamated epithelial cell pool probably due to decreased proliferation of the adult 
stem cell. Based on this, hypoplasia being a more reasonable concept explaining 
epithelial “thinning” than that of “atrophy”. The possible genotoxic and cytotoxic 
effects of NO on adult stem cells of epithelium and supporting stroma  supports  
further impetus to this concept
69
. 
 Regulation of transglutaminase-2 (TGM-2) by arecoline in oral fibroblasts 
have been found to play a major role in stabilizing the ECM proteins by cross-linking 
and making them highly resistant to protease degradation. This results in the 
accumulation of ECM, leading to fibrosis in OSMF cases. The expression of TGM-2 
was studied in OSMF tissues by real-time RT-PCR analysis, and significant 
overexpression was observed in most OSMF tissues (p=0.0112) compared with 
normal tissues
70
.
 
Currently the pathogenesis of OSMF have focused on heme oxygenase-1 
(HO-I) expression in fibrosis. HO-I, a microsomal enzyme, responsible for 
maintaining the cellular homeostasis. It plays an important protective role in the 
tissues due to reducing oxidative injury and attenuating inflammatory response. HO-I 
is consistently and dramatically upregulated in a variety of fibrotic diseases, such as 
benign prostatic hyperplasia and cystic fibrosis of lung. OSMF demonstrated 
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significantly higher HO-I mRNA expression than normal buccal mucosa on 
immnuhistochemistry. Arecoline was also found to elevate HO-I mRNA expression 
in a dose-dependent manner
71
. 
 
As OSMF produces changes localized to oral cavity, it has been put forth that 
saliva may have a role in the pathogenesis of OSMF. Saliva of OSMF patients have 
shown increased pH, increase in salivary amylase, increase in alkaline phosphatase 
and potassium, low level of calcium and normal level of salivary immunoglobulin. 
Formation of coagulum was observed in greater number of cases as the severity of 
the disease increased. It is thus postulated that the mechanical trauma due to chewing 
of betel nut, tobacco and chemical burns from slaked lime result in 
microhaemorrhage. The factor responsible for coagulum in saliva precipitates the 
increased laying down of fibroblast
72
. Increase in immunoglobulin levels is typically 
associated with three main chronic disease classes: those affecting the liver, collagen 
and chronic infections.  The severity of OSMF was directly  proportional to the 
estimated elevated levels of the major  immunoglobulins IgG and IgA
73
. 
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MULTIFACTORIAL MODEL FOR PATHOGENESIS OF OSMF  
 ( Bold arrows show effects mediated by various factors through the immune system, 
whereas broken arrows show possible direct effects of the factors on the  oral mucosa. ) 
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PHARMACOLOGY OF PENTOXIFYLLINE 
Pentoxifylline (oxpentifylline) is a tri-substituted methylxanthine derivative, 
chemically it is 1-(5-oxyohexyl)-3, 7dimethylxanthine, 1-(5oxyohexyl) theobromine.  
MECHANISM OF ACTION
 
  Pentoxifylline has potent rheologic modifying effects. Pentoxifylline and its 
metabolites blocks red cell aggregation, lower blood viscosity, inhibits microvascular 
constriction, and stimulates fibrinolysis. It also has significant anti-inflammatory, 
antifibrotic and immunomodulatory effects
74
. 
Effect on blood viscosity and flow 
 Increased red cell deformability and aggregation 
 Decreased circulating plasma fibrinogen 
 Decreased vasoconstriction. 
Immunologic effects  
 Increased leukocyte deformability 
 Decreased leukocyte adhesion and aggregation 
 Decreased neutrophil superoxide release and degranulation 
 Decreased neutrophil priming by platelet activating factor 
 Increased leukocyte chemotaxis 
 Decreased monocyte TNF-α production 
 Decreased leukocyte response IL-1 production 
 Decreased natural killer cell activity 
Effect on coagulation and fibrosis 
 Decreased platelet adhesion and aggregation 
 Increased tissue plasminogen activator and plasmin 
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 Increased antithrombin III 
 Decreased α2- Antiplasmin and α1 -  Antitrypsin 
Effect on wound healing and connective tissue 
 Increased fibroblast collagenases 
 Decreased fibroblast collagen and fibronectin 
 Decreased fibroblast glycosaminoglycans 
 Decreased fibroblast response to TNF-α 
          Pentoxifylline improves membrane deformability by increasing the amount 
of membrane ATP. It also alters red blood cell membrane protein phosphorylation 
patterns, increase protein kinase activity and decrease Ca
2+ 
dependent K
+
 efflux
75
.
 
      The mechanism of action of pentoxifylline in increasing polymorphonuclear 
cell chemotaxis is multifactorial. Pentoxifylline causes a dose dependent increase in 
cyclic adenosine monophosphate (cAMP) in polymorphonuclear cells. Cytoskeletal 
interactions are important in neutrophil adhesion, chemotaxis, phagocytosis and 
superoxide production. Pentoxifylline may act as an adenosine analogue, modulating 
cytoskeletal interactions. Pentoxifylline inhibition of lymphocyte activation also 
involves a cAMP dependent pathway
76
. 
         The effect of pentoxifylline on decreased platelet aggregation can be 
explained on the basis of blocking of phosphodiesterase conversion of cAMP to 
AMP. Pentoxifylline stimulates vascular endothelium to release prostacyclin I2, 
which further inhibits platelet adhesion and aggregation.
116
 TNF-α has been 
implicated in disseminated intravascular coagulation by stimulating endothelial 
production of procoagulant tissue factor and decreasing endothelial thrombomodulin 
resulting in decreased protein C activation
77
.
 
Some of the beneficial effects observed 
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with pentoxifylline therapy for hypercoaguable states may be related to its anti-TNFα 
effects. 
         The results of experimental studies have shown that fibroblasts cultured in the 
presence of pentoxifylline produced twice as much collagenase activity and 
decreased amounts of collagen, glycosaminoglycans and fibronectin. Interleukin-1 
induced fibroblast proliferation is also inhibited by pentoxifylline
78
.
 
PHARMACOKINETICS 
        Pentoxifylline is administered through oral and intravenous routes. The drug 
is almost completely absorbed after oral administration. It undergoes a first-pass 
metabolism and the various metabolites appear in plasma very soon after absorption. 
Intestinal absorption is rapid, with peak plasma concentrations obtained at 3.2 hours. 
The drug is metabolized by red blood cells and the liver, with an elimination half-life 
of 3.4 hours. There is extensive enterohepatic circulation. More than 90% of 
absorbed pentoxifylline is excreted in urine in the form of six metabolic products. 
Pentoxifylline and  a seventh metabolite are not excreted in the urine of humans 
which have more pronounced physiologic effects than the primary drug
79
. 
DOSAGE AND ADMINISTRATION
 
         The recommended adult dosage of oral pentoxifylline is 400mg thrice daily 
with meals. Doses as high as 2200mg daily have been well tolerated in patients with 
severe peripheral vascular disease. 
 
Duration of 3 to 12 months may be required for 
noticeable improvement in fibrotic skin disorders or other fibrosis
80
. 
        Intravenous pentoxifylline is also available. Slow intravenous infusion 
beginning with 100mg/day is recommended with a daily increase in increments of 50 
mg. Although the maximum recommended adult dose is 300mg/day, doses as high as 
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600g twice a day have been used successfully to treat gangrenous arterial occlusive 
disease
81
.
 
PREPARATIONS COMMONLY AVAILABLE: 
          OxpentifyllineTab-400mg TNMSC (Tamilnadu Medical service corporation)  
          Trental Tab-400mg, (Sanofi-Aventis)    
ESTABLISHED CLINICAL APPLICATIONS
74
 
 Pentoxifylline being a FDA approved drug and is currently used for various 
disorders in the medical field without significant complications. 
Vasoocclusive disorders: 
 Peripheral vascular disease 
 Cerebral vascular disease 
 Diabetic vascular disease 
 Polycythemia vera 
 Ischemic heart disease 
 Chronic renal insufficiency 
Hypercoagulable states 
 Post operative thrombotic complications 
 Transient ischemic attacks 
ADVERSE EFFECTS 
82 
        Most side effects caused by pentoxifylline involve the gastrointestinal tract and 
central nervous system. Nausea, vomiting, indigestion, gastric irritation, headache, 
dizziness are the commonly reported side effects. 
DRUG INTERACTIONS 
  Patient on oral anticoagulant are at higher risk of prothrombin time elevations 
when combining with pentoxifylline. Hence patients on warfarin should have more 
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frequent monitoring of prothrombin time. Patients with other risk factors like 
hemorrhage (e.g.,recent surgery, peptic ulceration) should have periodic 
examinations for bleeding including hematocrit and/or hemoglobin. 
  Combination of pentoxifylline and theophylline should be avoided which 
leads to increased serum theophylline levels and toxicity in some individuals
83
. 
Pentoxifylline has been used concurrently with antihypertensive drugs, beta blockers, 
digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed 
problems.  
  Small decrease in blood pressure has been observed in some patients treated 
with pentoxifylline, periodic systemic blood pressure monitoring is recommended for 
patients receiving concomitant antihypertensive therapy. If indicated, dosage of 
antihypertensive agents should be reduced.  
CONTRAINDICATION 
         Pentoxifylline should not be used in patients with recent cerebral or retinal 
hemorrhage or in patients who have previously exhibited intolerance to the drug or 
other methylxanthines such as caffeine, theophylline and theobromine. 
PENTOXIFYLLINE AND OSMF       
         Pentoxifylline  with potent hemorrheologic properties has been proved to be 
effective in treating intermittent claudication
84
. It was therefore convicted that it 
might also be effective in treating OSMF which having mucosal ischemia and 
epithelial atrophy.
 
The submucosal fibrosis, which is the hallmark of this disorder, is 
considered to be the result of a defective inflammatory reparative response resulting 
in fibrotic healing
85
. 
        The anti-inflammatory and immunomodulatory actions of pentoxifylline 
seems to have definite therapeutic implication in the management of OSMF. As 
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OSMF is a chronic inflammatory disease, control of the inflammation or the factors 
influencing the inflammatory changes should form the basis of definitive 
management. Pentoxifylline has the ability to decrease the production of tumour 
necrosis factor alpha (TNF-α), an important mediator of the inflammatory process86. 
         Primary immunologic abnormalities have also been reported in OSMF which 
probably mediate local tissue damage. The immune-modulating actions of 
pentoxifylline include decreased leukocyte adhesion, aggregation and degranulation, 
decreased superoxide release and decreased natural killer cell activity
87
.  
         OSMF is considered to be a collagen metabolic disorder with abnormal 
accumulation of collagen in subepithelial layers. An increased production and a 
reduced degradation of the type I collagen have been observed in OSMF. 
Collagenases are the only proteinases which specifically cleave triple helical 
collagen at neutral pH. A reduced content of functional collagenase observed in 
OSMF might be one of the mechanisms responsible for this collagen accumulation.
 
Fibroblasts cultured in the presence of pentoxifylline produce twice as much 
collagenase activity and decreased amount of collagen, glycosaminoglycans and 
fibronectins
88
.    
         Cytokines play an important role in regulating fibroblast function, such as 
proliferation, migration and matrix synthesis, hence it is likely to play a key role in 
regulating the initiation and progression of any fibrotic disease. Both interleukin-1 
(IL-1) and tumour necrosis factor alpha (TNF-α) stimulate fibroblast proliferation in 
vitro
 
and intradermal injections of TNF-α stimulate the accumulation of fibroblasts 
and collagen. Similarly, both IL-6 and IL-8 have been implicated in the development 
of fibrosis. Studies conducted in OSMF `patients have shown increased levels of 
proinflammatory cytokines: IL-1, IL-6, IL-8 and TNF-α and reduced anti-fibrotic 
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cytokine interferon gamma (IFN-γ) which may be central to the pathogenesis of 
OSMF. Interleukin -1 induced fibroblast proliferation was inhibited by 
pentoxifylline. In addition, pentoxifylline blocked the TNF-α induced synthesis of 
fibroblast collagen, glycosaminoglycans and collagenolytic activity
89
. 
          A randomized clinical trial was conducted to determine the effects of 
pentoxifylline on the clinical and pathological course of OSMF. The results showed 
highly significant improvement in mouth opening (p=0.000), tongue protrusion 
(p=0.002), relief from perioral and buccal mucosal fibrotic bands (p=0.000), burning 
sensation of mouth (p=0.0005), tinnitus (p=0.00004), difficulty in swallowing 
(p=0.00007) and speech (p=0.000) in all the test subjects. Adverse effects reported 
were mild gastritis and gastric irritation, peripheral flushing that could be managed 
easily. The study concluded that pentoxifylline is an effective adjunct therapy in the 
routine management of OSMF
43
.
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PRINCIPLES OF ULTRASONOGRAPHY 
An image is a reproduction, representation, or imitation of the physical form 
of a person or thing. An ultrasound image is the visible counterpart of an invisible 
object, produced by an electronic instrument. Ultrasound provides a non-invasive 
way of looking inside the human body to image otherwise unseen anatomy. 
Anatomic imaging with Ultrasound is accomplished with a pulse echo technique.  
Ultrasound is defined as the sound above the range of human hearing i.e., 
above the frequency of 20,000 Hz (normal human hearing is between 20 Hz – 20,000 
Hz). Ultrasonic waves require a medium for their propagation, since they cannot 
travel in vacuum. The use of ultrasound to obtain diagnostic information is called 
Ultrasonography. Medical use of ultrasound involves frequencies greater than 3 
MHz.  
ULTRASOUND PRODUCTION:   
In an ultrasound machine, ultrasound is produced by passing electric current 
through Piezo – electric crystals (PZE) contained in its “transducer” portion. PZE 
crystals have the unique property of “interconverting” various forms of energies as 
follows. All PZE crystals possess” large” loosely held charged atoms which shift in 
response to the applied electrical field which in turn leads to the following two 
changes  
a. Change in shape of crystals with liberation of mechanical energy.  
b. Generation of vibration with liberation of sound energy. 
The reflected ultrasounds (echoes) are collected by the transducer (serves as a 
transmitter and receiver at the same time), in a reverse order than that of the 
piezoelectric effect, the sound waves are converted to mechanical energy first, and 
                                                           Principles Of Ultrsonography 
 
 34 
 
then to an electrical charge. Because of its acoustic impedance, a tissue has a 
characteristic internal echo pattern or echogenicity. Consequently, not only changes 
in the echo patterns delineate different tissues, but they can also be correlated with 
pathologic changes in a tissue
90
.
  
TRANSDUCERS: 
Pulses of ultrasound are generated by a transducer and are sent into the 
patient, where they produce echoes at organ boundaries and within tissues. These 
echoes then return to transducer, where they are detected and then presented on the 
display of a sonographic instrument. A transducer converts one type of energy into 
another. Based upon the pulse-echo principle occurring with ultrasound piezoelectric 
crystals, ultrasound transducers convert:
 17
 
 Electricity into sound = pulse 
 Sound into electricity = echo 
Mechanism Of Conduction Of Ultrasound Through Tissues
91
: 
Ultrasound energy is transformed through tissue from “particle to particle and 
runs in the longitudinal wave form. The ultrasound energy which is passes to the 
tissue is directly related to the frequency of ultrasound energy used. The Ultrasonic 
waves are reflected and refracted at the boundary where two types of tissues with 
different acoustic impedance exist adjacent to each other. The acoustic impedance in 
bone is greater than that in soft tissues and therefore most of ultrasound waves reflect 
at the surface of bone but reflects very little from the inside of bone. A tissue such as 
the surface of bone is visualized as hyperechoic area.  
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ECHO MECHANISM OF ULTRASOUND:   
Echo generation : Ultrasound beam as it passes through various interphase 
of tissue gets partially reflected back from each of the interphase which constitutes 
the echo which can be specular or scattered.    
Echo – Receiving Mechanism:  In ultrasound transducer (probe) the 
arrangement is such that the same PZE crystals which produce ultrasound beam (on 
being stimulated by electric current) also serve to receive the returning ultrasound 
energy (echo) from the tissue.  
PZE crystals on receiving the echo convert it into “electrical energy” by its 
inherent property, which is then converted into high energy by the ultrasound 
machine, which is then visualized  as dots of light constituting a picture on a monitor.  
Chemistry of PZE Crystals:   
Ceramic: Quartz, barium, titanium (most commonly used). Being ceramic 
they are    very fragile and hence ultrasound transducers must be handled with 
great care. 
Plastic: Lately they are being synthesized and may allow a little rougher 
handling. These PZE crystals are coated as “thin plate” in the shape of a disc 
in the transducer.  
Metal electrode material is then deposited on both of its surface 
electrolytically.  Application of voltage across the electrode causes the plate to 
vibrate to produce ultrasound. The frequency of ultrasound produced is directly 
proportional to the thinness of the plate, i.e. thinner the plate, the higher the 
frequency of ultrasound
92
.  
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Different modes in ultrasound:  
 A – Mode (amplitude mode) is the simplest type of ultrasound. A single 
transducer scans a line through the body with the echoes plotted on screen as a 
function of depth. Therapeutic ultrasound aimed at a specific tumor or calculus is 
also A-mode, to allow for pinpoint accurate focus of the destructive wave energy.  
 B - Mode (Brightness modulation): Two dimensional display of the static 
image. The “B” mode produces a picture of a slice of tissue. Echoes are displayed as 
dots. 
C-mode: C-mode image is formed in a plane normal to a B-mode image. A 
gate that selects data from a specific depth from an A-mode line is used; then the 
transducer is moved in the 2D plane to sample the entire region at this fixed depth. 
When the transducer traverses the area in a spiral, an area of 100 cm
2
 can be scanned 
in around 10 seconds 
            M – Mode (motion mode): also called as real time scan. A real time system 
can produce multiple frames in a very short time. This fast frame rate allows 
movement to be viewed in “real time” as the images are generated.  
D-mode (D=Doppler) This imaging mode is based on the Doppler effect, ie. 
change in frequency (Doppler shift) caused by the reciprocal movement of the sound 
generator and the observer. Diagnostic ultrasound uses the change in frequency of 
ultrasound signal backscattered from red blood cells. The frequency of the reflected 
ultrasound wave increases or decreases according to the direction of blood flow. 
Gray Scale : It is a scale for quantification of echo signals which is nearest 
to help the interpretation of an ultrasound image. In gray scale imaging, strong 
echoes are displayed as light gray or white and weak echoes as dark gray or black. 
Between these, various shades of gray are displayed.  
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ADVANTAGES: 
 It’s a non invasive modality. 
 It images muscles and soft tissues very well and is particularly useful for           
delineating the interfaces between solid and fluid filled spaces. 
 It shows the internal structure of the organs. 
 No known long term side effects and early causes discomfort on pain to the 
patient. 
 Renders line images, where the operator can dynamically select the most 
useful section for diagnosing and documenting changes often enabling rapid 
diagnosis 
 Equipment is widely available and is comparatively flexible. 
 Small easily carried scanners are available and examinations can be easily 
preformed at the bed side. 
 Relatively inexpensive compared to CT & MRI. 17 
 
LIMITATIONS: 
 Obese patients limit image quality as the overlying adipose tissue scatters the 
sound and greater depth the sound waves need to travel, weaken the signal on 
transmission reflection back to the transducer. 
 Ultrasound performs very poorly when there is gas between the transducers 
and organ of interest due to extreme differences in acoustical impedance. 
 Ultrasound devices have trouble in penetrating bone. 
 Once an image is acquired there is no exact way to tell which part of the body 
was imaged. 
 Method is operator dependent high level of skill and experience is needed to 
acquire good quality images and make accurate diagnosis 
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USG is also a method for measurement of oral mucosa, which has been 
applied for measurement of gingival thickness in attached gingival, palatal mucosa, 
masticatory muscle thickness
48,50
.   
CLINICAL APPLICATIONS OF ULTRASONOGRAPHY IN ORAL MUCOSA: 
The echogenecity of a tissue primarily relates to its “stiffness”, the chief 
source of which is collagen, the content and arrangement of collagen with in tissue 
which is a major factor in modification of the manner and extent to which a tissue 
attenuates the acoustic wave. The applications of USG in head and neck region is for 
examination of the thyroid gland, the salivary gland, examination of fetal face and 
sonically guided surgery.   
USG provides both qualitative and quantitative assessment. Qualitatively it 
provides information on the nature of the swelling or lesion, whether it is soild or 
cystic, whether calcifications present, and relations of lesion to adjacent normal 
structures. Quantitatively it may assess the dimension of the lesion, its distance from 
the skin surface and its relative proximity to skin and mucosal surfaces -delineation 
of the mucosal surface often being aided by placement of a finger on that surface 
adjacent to field of view. Measurements are obtained atraumatically, rapidly and 
rather inexpensively. Suspect measurements may be repeated immediately, checked 
and averaged. Ultrasonic assessments of mucosal thickness in different parts of oral 
cavity may depend on the difficulties of repeatedly measuring at the same location, 
on varying thickness of tissue. These problems might be resolved by averaging 
multiple measurements. They also concluded that USG device yielded valid and 
relatively reliable information on thickness of most parts of masticatory mucosa. 
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MATERIALS AND METHODS 
The study was conducted after getting approval from the Institutional Ethical 
Committee. 
STUDY CENTRE: 
Department of Oral Medicine and Radiology, 
Tamil Nadu Government Dental College and Hospital,  
Chennai – 600 003. 
 
Bernard Institute of Radiology,  
Rajiv Gandhi Government Hospital,  
Chennai -600003. 
CASE SELECTION: 
 The study population include total of 30 patients, either of the sex who were 
diagnosed as OSMF based on habitual history and clinical findings which include the 
presence of burning sensation in the mouth, blanching and loss of stiffness of oral 
mucosa, presence of fibrous bands and restricted opening of mouth. Then the patients 
were selected who satisfying the following inclusion and exclusion criteria. 
Inclusion criteria: 
 Patient with age group of 20 to 60 years, both Gender.  
 Patients who satisfy the characteristic clinical features of OSMF  
 Patients who are not taking any medication for their disease condition. 
Exclusion criteria: 
 Patients with chronic systemic diseases like cardiac, cerebrovascular, 
Respiratory, Renal, Hepatic, Gastrointestinal complications, collagen 
disorders, infectious diseases, bleeding disorders and diabetes mellitus . 
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 Patients with severe restricted mouth opening (<15mm) 
 Pregnancy and lactation 
 Patient intolerance to caffeine and theophylline 
 Patients not willing to participate in the study. 
METHODOLOGY: 
Study subjects of 30 patients were included in the study based on inclusion 
and exclusion criteria, and those who satisfied the clinical criteria of OSMF. All the 
participants were explained about the need and design of the study, the drug therapy 
and their possible adverse effects (including gastric irritation, nausea, vomiting, 
dizziness), the need for thorough clinical examination, routine investigations and 
USG as a part of the study. Patients who gave a signed informed consent on an 
institutionally approved document were included in the study. Patient also subjected 
to routine blood investigation and Tobacco Cessation Counselling (TCC) in our 
institution before the start of the study and TCC were continued during the progress 
of the study. 
A detailed case history of the patient with emphasis on their habits (chewing 
betel nut, pan parag, etc.) and a thorough clinical examination was recorded on a 
structured proforma designed for the study. A clinical diagnosis of OSMF was made 
and patients were numbered serially as they entered the study. 30 subjects were 
included conveniently in the study in single blind randomised manner to the 
following groups alternatively irrespective of age, sex and stage of OSMF. 
GROUP A: Pentoxifylline group 
 GROUP B: Dexamethasone group 
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Then patients were graded clinically after assigned to the group, according to 
Khanna JN, Andrade NN (1995)
93
,  
     Group I:  Very early cases:  
     Normal mouth opening 
     Burning sensation in the mouth,  
     Acute ulceration and recurrent stomatitis. 
 Group II: Early cases 
Interincisal distance of 26 to 35 mm. 
Buccal mucosa appears mottled and marble like,  
Widespread sheets of fibrosis palpable and red erythematous patches  
 Group III: Moderately advanced cases 
 Interincisal distance of 15 to 25 mm, 
 Buccal mucosa appears pale firmly attached to underlying tissues,  
 Atrophy of vermilion border, 
 Vertical fibrous bands palpable at the soft palate, pterygomandibular 
raphe   and anterior faucial pillars. 
Group IVA: Advanced cases 
         Severe trismus, 
                       Interincisal distance of less than 15 mm, 
              Restricted tongue movement,  
              Presence of circular band around entire lip and mouth. 
                      Thickened faucial pillars, shrunken uvula 
 Group IVB : Advanced cases with premalignant and malignant changes 
   Oral submucous fibrosis and leukoplakia 
              Oral submucous fibrosis and squamous cell carcinoma. 
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Armamentarium: 
Examination of the patient:[Figure 1] 
 Electrically operated dental chair 
 Patient’s apron 
 Disposable mouth mask 
 A pair of disposable latex examination gloves 
 Stainless steel kidney trays 
 Mouth mirror 
 Stainless steel probe 
 Tweezer 
 Divider and Metallic scale 
Drug administration:[Figure 2] 
 Sterile 3 ml disposable syringe 
 Tablet oxpentifylline 400mg  
 Topical local anesthetic gel  
 Injection Local anaesthesia  
 Injection dexamethasone 2ml vial  
o Injection hyaluronidase 1500 IU (HYNIDASE- shreya pharma ) 
All the drugs are supplied by TNMSC except HYNIDASE . 
Ultrasonographic evaluation:[Figure 3 & 4] 
 Philips high frequency ultrasound machine (3 – 12 MHz )  
 Linear Transducer  measuring 4 X 1 cms  
 Acoustic coupler (Coupling agent)   
(Carbomer–10g, EDTA-.25g, Propyleneglycol-75g, Trolamine -12.5g) 
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COLLECTION OF DATA: 
 Patients were made to sit comfortably on a dental chair. Clinical examination 
was carried out wearing sterile hand gloves and mouth mask under artificial 
illumination including blanching of mucosa [Figure 5-7] and fibrous band palaption. 
Brief medical history was taken to rule out any possible systemic illness. 
 Clinical parameters included in the study to evaluate the effectiveness of the 
drugs were burning sensation and mouth opening. USG parameters included were 
submucosal thickness and echogenicity. 
The intensity of burning sensation was determined using a Visual Analogue 
Scale (VAS) of 0-10 with 10 mm division, where 0 was no burning sensation and 10 
was worst possible burning sensation. The patients were asked to mark VAS at a 
point which best represented their level of symptoms. The score was recorded at each 
subsequent visit after the administration of the drug therapy. 
The interincisal mouth opening was measured using divider and scale from 
the mesio-incisal angle of upper central incisor to the mesio-incisal angle of lower 
central incisor and recorded in centimetres [Figure 8]. If the corresponding teeth 
were not present contra lateral teeth or adjacent teeth will be considered. Intraorally, 
different sites were examined for blanching of the mucosa, consistency, fibrous 
bands, and for presence of other lesions. 
  Complete haemogram and random blood sugar examination was done for all 
patients, then subjected to pre operative USG evaluation. Oral prophylaxis was 
carried out in all the patients before USG evaluation.  
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ULTRASONOGRAPHIC EVALUATION: 
 Ultrasonographic measurements of submucosal thickness  and echogenicity 
were performed for 30 subjects comprising of 15 in each groups. Scanning was 
performed with the patient in supine position. The patients were positioned such that 
their head was in level with the examiners knees. The examiner was  sat on the right 
side of the patient where the ultrasound apparatus was also placed. The ultrasonic 
transducer was cleaned by an antiseptic solution using surgical spirit. Coupling agent 
was applied on the linear transducer and also on the area of interest. Ultrasound 
examinations were performed by a single trained general Radiologist.   
   Transcutaneous imaging was done using ENVISOR CHD (Philips company) 
with multifrequency linear transducer with a frequency ranging from 3-12 MHz 
which was connected to the scanner. Transducer measures about 4 cms in length and 
1 cm in width. With focal depth of approximately 6mm- 1cm.And a real time 
imaging of buccal mucosae was performed. Buccal mucosa was selected for USG 
evaluation as it is commonly involved next to faucial pillar and it is easily 
approachable for proper evaluation. 
  The transducer probe was placed in such a way that the soft tissues were not 
unduly compressed, because excess contact pressure while imaging might affect the 
measurements. Hence, to get the exact thickness measurements the probe was 
brought softly onto contact with the surface.  
Patients were prior instructed to indicate the mucosa by placing the forefinger 
inside the mouth against the mucosa to delineate the lining mucosa and empty space 
of the oral  cavity as stated by Wilson et al
14
.  He also told that to assess distance 
from the skin surface and  its relative proximity to skin and mucosal surfaces, 
delineation of the mucosal surface can often being aided by placement of finger on 
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the surface adjacent to field of view [Figure 10]. Patients were also told not to apply 
finger pressure against the mucosa but just a finger touch movement of the mucosa. 
For imaging the right buccal mucosa, patients left forefinger was used as an indicator 
and for left buccal mucosa corresponding right forefinger was used as an indicator. 
Once the patient moves the indicator finger against the mucosa a corresponding 
movement of mucosal lining was visualized on the monitor.   
The real time imaging of submucosa of right and left buccal were carried on 
and the measurements were taken. Mucosal lining was seen as a hyperechoic linear 
line, submucosa as a band of hypoechoic zone supported by a muscle planes in 
controls. This band of hypoechogenicity in between hyperechoic mucosa and muscle 
layer was measured as submucosa. All measurements were taken in centimetres 
[Figure 11 & 12]. With increased severity of OSMF submucosa is thought to become 
more hyperechoic compared to hypoechoic in normal patients. Hyperechogenicity is 
marked as 1 and hypochogenicity is marked as 2. Since differences in reliability of 
ultrasonic assessments of mucosal thickness in different parts of oral cavity may 
depend on the difficulties of repeatedly measuring at the same location, on varying 
thickness of tissue. These problems might be resolved by averaging multiple 
measurements. 
METHOD OF DRUG ADMINISTRATION: 
 After pre-operative USG evaluation, patient in Group A were administered 
oral pentoxifylline 400mg thrice daily after meals for 3 months and patient in group 
B were administered intralesional injection of 0.5ml of local anaesthesia with 2ml of 
dexamethasone and 1500 I.U of Hyaluronidase Bi-weekly for 6 weeks [Figure 9].  
Patient in Group A were recalled and evaluated for improvement in signs and 
symptoms for every 3 days for first month and then every week for next two months. 
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Final changes in burning sensation and mouth opening were recorded after the 
complete course of treatment. Similarly patient in Group B were evaluated during 
every injection and values were recorded after the end of the course of injection. 
POST OPERATIVE USG EVALUATION: 
 After the course of the treatment scheduled, all the patients of both the groups 
were subjected to post operative USG evaluation of submucosal thickness and 
echogenicity similar to pre-operative evaluation and the values are recorded. All the 
values were statistically analysed and the results were drawn. 
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FIGURE 1 : DIAGNOSTIC  INSTRUMENTS 
 
FIGURE 2: DRUGS  USED IN THE STUDY 
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FIGURE 3 : ULTRASOUND MACHINE 
 
FIGURE 4: COUPLING AGENT AND TRANSDUCER 
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 FIGURE 5: BLANCHING OF BUCCAL MUCOSA
  
FIGURE 6 : BLANCHING OF LABIAL MUCOSA
 
FIGURE  7 : BLANCHING OF SOFT PALATE       
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FIGURE 8:MOUTH OPENING MEASUREMENT 
 
FIGURE 9:INTRALESIONAL INJECTION THERAPY 
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 FIGURE  10 : POSITIONING OF PATIENT FINGER AND TRANSDUCER 
 
FIGURE 11 : USG EVALUATION -  PRE OPERATIVE
 
FIGURE 12: USG EVALUATION  – POST OPERATIVE            
 
MASTER CHART  :  GROUP A – PENTOXIFYLLINE 
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BURNING 
SENSATION 
MOUTH OPENING 
(mm) 
ST
A
G
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G
 
USG SUBMUCOSAL  THICNESS 
(mm) 
SUBMUCOSAL ECHOGENICITY 
(HYPER -1 : HYP0 -2) 
PRE 
OP 
POST 
OP 
PRE 
 OP 
POST 
OP 
PRRE OP  POST OP 
 
PRRE OP PRRE OP  
RIGHT LEFT RIGHT LEFT RIGHT LEFT RIGHT LEFT 
1 23 M 7 0 25 29 III 0.63 0.54 0.45 0.36 1 1 2 2 
2 29 M 5 0 35 41 II 0.48 0.46 0.29 0.26 1 2 2 2 
3 32 F 6 0 23 28 III 0.47 0.63 0.34 0.41 2 1 2 2 
4 36 M 7 0 20 24 III 0.83 1.12 0.64 0.84 1 1 2 2 
5 25 M 10 0 19 23 III 1.06 0.98 0.83 0.76 1 1 1 1 
6 29 F 5 0 22 25 III 0.61 0.87 0.38 0.63 1 1 2 1 
7 45 M 10 0 26 29 II 0.65 0.64 0.45 0.44 1 1 2 2 
8 38 M 3 0 24 31 III 0.78 0.65 0.52 0.45 1 1 2 2 
9 47 M 5 0 29 34 II 0.65 0.75 0.46 0.52 1 1 2 2 
10 36 M 10 0 26 29 II 0.85 0.55 0.53 0.33 1 2 2 2 
11 29 M 7 0 24 29 III 0.61 0.87 0.42 0.63 2 1 2 2 
12 33 F 2 0 23 27 III 0.68 0.83 0.41 0.61 1 1 1 2 
13 32 M 5 0 21 24 III 0.89 0.78 0.62 0.51 2 1 2 2 
14 43 M 8 0 32 38 II 0.64 0.63 0.41 0.39 2 1 2 2 
15 54 M 10 0 35 42 II 0.65 0.67 0.48 0.46 1 1 2 2 
 
MASTER CHART  : GROUP B – DEXAMETHASONE WITH HYALURONIDASE 
S.
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BURNING 
SENSATION  
MOUTH OPENING 
(mm) 
ST
A
G
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G
 USG SUBMUCOSAL  THICNESS 
(mm) 
SUBMUCOSAL ECHOGENICITY 
(HYPER -1 : HYP0 -2) 
PRE 
OP 
POST 
OP 
PRE 
 OP 
POST 
OP 
PRRE OP  POST OP 
 
PRRE OP PRRE OP  
RIGHT LEFT RIGHT LEFT RIGHT LEFT RIGHT LEFT 
1 32 M 5 0 31 33 II 0.66 0.68 0.53 0.54 1 1 2 2 
2 28 M 7 0 25 28 III 0.66 0.93 0.68 0.77 1 2 1 1 
3 25 F 3 1 16 18 III 1.06 0.83 0.93 0.66 1 1 1 2 
4 43 M 8 0 28 31 II 1.03 0.96 0.88 0.82 1 1 1 1 
5 35 M 10 0 30 32 II 0.67 0.43 0.49 0.32 2 1 2 2 
6 39 M 6 0 18 21 III 0.93 1.08 0.82 0.96 1 1 1 1 
7 27 M 5 0 29 33 II 0.92 0.74 0.78 0.61 1 2 1 2 
8 36 F 7 0 19 21 III 0.88 0.73 0.74 0.59 1 1 1 1 
9 42 M 3 1 35 38 II 0.84 0.74 0.71 0.61 1 1 2 2 
10 29 M 10 0 26 29 II 0.44 0.46 0.32 0.33 2 1 2 2 
11 23 M 6 0 30 32 II 0.62 0.64 0.54 0.55 1 1 2 2 
12 26 M 7 0 25 29 III 0.66 0.68 0.53 0.55 1 1 2 2 
13 43 M 4 0 32 34 II 0.52 0.55 0.42 0.41 1 1 2 2 
14 38 F 9 0 33 36 II 0.45 0.54 0.36 0.38 2 1 2 2 
15 26 M 8 0 31 34 II 0.72 0.65 0.58 0.53 1 1 1 2 
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STATISTICAL ANALYSIS  
The statistical analysis was done using the computer software program SPSS 
version 18. 
 The percentage of distribution of age groups, sex was calculated within each 
group and overall distribution was also calculated. The overall distribution of stages 
of osmf was calculated among the study population. Distribution of burning 
sensation, mouth opening and submucosal thickness was also calculated in relation to 
stages.  
 Arithmetic mean and standard deviation were estimated for different 
variables in each study group. 
 Independent sample test were used to analyse association of staging with 
different vaiables used in this study. Paired sample test were used to analyse 
variables within each group. Independent t test were used to analyse variable 
between groups. Pearson Co-relation test were used to find correlation between 
mouth opening and submucosal thickness. 
In the present study, p < 0.05 was considered as the level of significance. 
 
 
 
 
 
 
 
 
 
                                                                         Statistical Analysis 
 
 48 
 
TABLES 
TABLE 1: DEMOGRAPHIC DISTRIBUTION: 
  GROUP A GROUP B 
AGE 
(YEARS) 
MEAN AGE 35.4 32.8 
RANGE 23-54 23-43 
SEX 
(N=30) 
MALE 12 12 
FEMALE 3 3 
 
TABLE 2: PREVALENCE OF STAGE: 
 GROUP 
A(n=15) 
GROUP B 
(n=15) 
overall (n=30) 
STAGE II 6 (40%) 10(66.6%) 16 (53.3%) 
STAGE II 9 (60%) 5 (33.3%) 14(46.6%) 
 
TABLE 3: ASSOCIATION BETWEEN STAGE AND VARIABLES  
 BURNING 
SENSATION(mean 
VAS score) 
MOUTH 
OPENING (mm) 
USG SUBMUCOSAL 
THICKNESS (mm) 
STAGE II 
7 29.4 (26-36) 0.66 
STAGE III 
6.6 21.2(16-25) 0.82 
p value  .234 .000
** 
.006 
              ** - Highly significant 
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TABLE 4: COMPARISION OF BURNING SENSATION BETWEEN GROUPS 
  PRE-OPERATIVE POST-OPERATIVE  
GROUP No. of 
patients 
Mean standard 
deviation 
Mean standard 
deviation 
p value 
GROUP 
A 
15 6.66 ±2.58 0.00 ±0.00 0.000
** 
GROUP 
B 
15 6.53 ±2.26 0.13 ±0.35 0.000** 
 ** - Highly Significant 
TABLE 5: EVALUATION OF MOUTH OPENING IN GROUP A OSMF  
GROUP A No. Of 
patients 
Mean Standard 
Deviation 
p value 
BEFORE 15 25.66 ±5.32738 
0.000** 
AFTER 15 30.20 ±6.02613 
DIFFERENCE 15 4.53 ±1.18723 0.000** 
: ** - Highly Significant 
TABLE 6 : EVALUATION OF MOUTH OPENING IN GROUP B OSMF  
GROUP B No. Of 
patients 
Mean Standard 
Deviation 
p value 
BEFORE 15 27.20 ±5.69712 
0.000** 
AFTER 15 29.93 ±5.79984 
DIFFERENCE  2.73      ±0.70373 0.000** 
 ** - Highly Significant 
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TABLE 7: COMPARISION OF SUBMUCOSAL THICKNESS - GROUP A 
 NO.OF 
SAMPLES 
Mean 
Standard 
deviation 
Mean 
Standard 
deviation 
 
p value 
 
RIGHT 
SIDE 
15 0.69 ±0.15 0.48 ±0.13 0.000
** 
LEFT 
SIDE 
15 0.69 ±0.15 0.48 ±0.13 0.000** 
BOTH 
SIDES 
30 .7150 ±.16604 .4943 ±.14628 0.000** 
     ** - Highly Significant 
TABLE 8: COMPARISION OF SUBMUCOSAL THICKNESS - GROUP B 
 NO.OF 
SAMPLES 
Mean 
Standard 
deviation 
Mean 
Standard 
deviation 
 
p value 
 
RIGHT 
SIDE 
15 .74 ±0.19 .62 ±0.18 0.000** 
LEFT 
SIDE 
15 .70 ±0.18 .57 ±0.17 0.000** 
BOTH 
SIDES 
30 .7290 .18830 .5980 .18199 0.000** 
      ** - Highly Significant 
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TABLE 9: COMPARISION OF ECHOGENICITY GROUP A 
 
 
PRE OPERATIVE POST OPERATIVE  
 No.of 
Samples 
Hyper Hypo Hyper Hypo P value 
RIGHT 
SIDE 
15 11 4 .2 13 0.040* 
LEFT 
SIDE 
15 13 2 2 13 0.010* 
BOTH 
SIDE 
30 24 6 4 26 0.000
** 
   a - binomial distribution used, 
*
 -significant,
   
** - highly significant 
 
TABLE 10: COMPARISION OF ECHOGENICITY GROUP B 
 
 
PRE OPERATIVE POST OPERATIVE  
 No.Of 
Samples 
Hyper Hypo Hyper Hypo 
p value 
RIGHT 
SIDE 
15 12 3 7 8 0.062 
LEFT 
SIDE 
15 13 2 4 11 0.012* 
BOTH 
SIDE 
30 25 5 11 19 0.001* 
        a 
binomial distribution used
, 
* -significant,
  
** - highly significant
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TABLE 11: COREALTION OF MOUTH OPENING WITH SUBMUCOSAL 
THICKNESS – GROUP A 
 
PEARSON CORELATION 
 
MOUTH 
OPENING POST 
OP (p value ) 
 
USG PRE OP 
SUBMUCOSAL 
THICKNESS (p value) 
 
MOUTH OPENING 
PRE OP 
N=15 
 
GROUP 
A 
0.986
**
(0.00) - 0.534
*
(.041) 
 
GROUP 
B 
 0.993** (0.00) - 0.549*(.034) 
 
USG PRE OP 
SUBMUCOSAL 
THICKNESS 
N=15 
 
GROUP 
A 
- 0.530
*  
(0.042) 0.977
**
(.00) 
 
GROUP 
B 
- 0.517
*
(0. .049) 0.993
**
(.00) 
 * -significant,  ** - highly significant 
TABLE 12: PERCENTAGE OF IMPROVEMENT IN MOUTH OPENING 
AND SUBMUCOSAL THICKNESS 
 
          % 
MOUTH 
OPENING 
 SUBMUCOSAL THICKNESS 
RIGHT LEFT OVERALL 
 
GROUP A 
 
17.66% 
 
31.01% 
 
30.72% 
 
30.86% 
 
GROUP B 
 
10.04% 
 
17.09% 
 
18.89% 
 
17.99% 
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RESULTS AND OBSERVATIONS 
 A total of 30 patients diagnosed clinically as OSMF were included in the study. 
The patients were assigned to two groups  
  Group A were administered pentoxifylline (oxypentifylline) 400 mg thrice 
daily for 3 months 
 Group B were administered intralesional injection of 0.5ml of LA with 1ml of 
dexamethasone and 1500 I.U of hyaluronidase biweekly for 6 weeks. 
Burning sensation, mouth opening clinically, Submucosal thickness and 
submucosal echogenicity of buccal mucosa was measured using high frequency 
ultrasonograpy in both the groups, preoperatively and postoperatively. 
 A total of 30 patients with age ranging from 23- 54 years, with the mean age 
being 35.4 years in group A and 32.8 years in group B, were included in the study . 
The maximum number of subjects was in the age group of 26 – 30 years and 
minimum were in 46 -55 years of age. Out of 30 subjects enrolled in the study 14 
were males and 6 were females. A male predilection was observed [TABLE 1] 
[CHART 1 & 2]. 
 In the present study, stage II is more prevalent than stage III were observed, 
19 patients in stage II and 11 patientss in  stage III. This is correspond to the study 
conducted by Anjum aara et al
45
 who also reported with increased prevalence of 
stage II compared to stage III [TABLE 2] [CHART 3 & 4]. Association of stages of 
OSMF with various variables in the study also analysed [TABLE 3] [CHART 5 -7]. 
 In the present study, all the patients in group A showed complete reduction in 
burning sensation and 2 pstients in group B showed mild persistance of burning 
sensation after medication. But both the groups showed highly significant reduction 
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(p<0.001) in burning sensation [TABLE 4] [CHART 8]. A study conducted by 
Rajendran et al,  reported statistically significant improvement in burning sensation 
in 14 patients treated with pentoxifylline for a period of 7 months
43
. 
 In the present study all patients in both groups showed highly significant 
increase in mouth opening (p<0.001), but group A showed marginally higher degree 
of improvement (mean- 4.53mm) compared to group B (mean – 2.73 mm) [TABLE 
5 & 6] [CHART 9]. The maximum increase in mouth opening was 7mm and the 
minimum was 3mm in group A whereas it is 4mm and 2mm respectively in group B.  
 In the present study, the overall mean pre-operative submucosal thickness of 
buccal mucosa is about 0.722 mm which range from 0.43mm to 1.12mm. The mean 
pre operative submucosal thickness of buccal mucosa in group A is about .715 
±.166mm which range from 0.46 mm to 1.12mm, for right side it is about 
0.698±.157 mm and for left side is about 0.731±.157mm. However in a study 
conducted by Devathambi et al (2013)
94
, mean submucosal thickness of buccal 
mucosa range from 0.90mm to 2.61mm.The overall mean post operative submucosal 
thickness of buccal mucosa in group A is about 0.4943±.14628mm which range from 
0.26 mm to 0.84mm, for right side is about .482±.134 mm and for left side is about 
.506±.161mm, both are found to be highly significant [TABLE 7] [CHART 10]. 
This is the first study which evaluates the post operative submucosal thickness of 
buccal mucosa after medication.  
In case of group B , mean submucosal thickness is about .729±.188mm which 
range from 0.43 mm to 1.08mm, whereas in right side is about .748±.197mm and for 
left side is about .709±.183mm. The overall improvement is about .598±..181mm 
which range from 0.43 mm to 1.08mm, whereas in right side is about 
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.6207±.18786mm and for left side is about .5753±.17948, which also showed highly 
significant value [TABLE 8] [CHART 11]. 
 In the present study, McNmer test is used to evaluate the echogenicity 
because of binomial distribution of values. Pentoxifylline group showed significant 
resulst in echogenicity on both right and left side (p<0.005) individuallyand 
combined together showed highly significant result (p<0.001) [TABLE 9] [CHART 
13&14]. 
 Dexamethasone group also showed similar significant result individually and 
highly significant result on combined together of both sides [TABLE 10]. This is the 
first study which evaluates echogenicity of submucosa on OSMF patients to analyse 
the outcome of different medical mode of treatment. 
 Comparision of improvement in mouth opening and submucosal thickness 
after treatment was evaluated on both groups using Pearson correlation. Both showed 
highly significant result(p<0.001) on both groups . Cross comparison of mouth 
opening with submucosal thickness was also done on both groups, which showed 
significant result (p<0.05) on both the groups [TABLE 11] [CHART 15].This 
implies that both medical mode of treatment are effective in improving clinical 
symptoms. 
 This present study also concluded that the group A showed 17.66% 
improvement in mouth opening and 30.86% improvement in submucosal thickness 
compared to 10.04% and 17.99% improvement in group B patients respectively 
[TABLE 12] [CHART 16]. This data clearly signifies that both the pentoxifylline 
and intralesional injection of dexamethasone with hyaluronidase are effective in the 
management of OSMF patients, but pentoxifylline have little edge over it.  
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DISCUSSION 
 Oral submucous fibrosis is a chronic debilitating pre-malignant condition 
affecting millions of individuals worldwide and most commonly seen in the Asian 
subcontinent. The prevalence in India ranges from 0.2%-1.2%
5
  and malignant 
transformation rate of 3-7.6%
95
. Despite extensive research, the etiology of OSMF 
still remains largely unknown and the pathogenesis is yet to be completely 
elucidated. Several factors such as chili consumption, areca nut chewing
7
, nutritional 
deficiencies
96
, genetic susceptibility
28
, autoimmunity
 
and collagen disorder have been 
suggested to be involved in the pathogenesis of this condition.
 
 Based on clinical, 
epidemiological and in vitro studies, areca nut chewing is considered as the 
important predisposing factor. 
Various modalities were proposed for the treatment of OSMF. Medical 
treatments were designed to increase the mouth opening and improve other signs and 
symptoms associated with this disease. The different categories of drugs used include 
steroids, antioxidants, immunised cow milk
9
, colchicine
10
, vitamins, microelements, 
enzymes, vasodilators and immunomodulators.  
The present drug treatments in general are empirical at best and a definitive 
cure for the disease still remains elusive. Currently intralesional steroid with or 
without hyaluronidase is considered to be the effective medical management for 
OSMF.  But because of the painful injection, need of attention towards frequent 
visits, dexterous skill for submucosal injection warrant the intralesional therapy quite 
unsatisfactory.  
Pentoxifylline, a methylxanthine derivative with potent hemorrheologic 
properties, was therefore considered to be effective in treating OSMF. The anti-
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inflammatory and immunomodulatory actions of pentoxifylline seems to have 
definite therapeutic advantage in the management of OSMF. As OSMF is a chronic 
mucosal inflammatory disease, control of the inflammation or the factors influencing 
the inflammatory process should form the basis of definitive management. 
Pentoxifylline has the ability to decrease the production of tumour necrosis factor 
alpha (TNF-α), an important mediator of the inflammatory response.The property of 
pentoxifylline that may be far reaching in the management of OSMF is possibly its 
inhibitory effect on fibroblast proliferation and fibrinolysis.  
Most of the changes associated with OSMF are an irreversible process, 
treatment outcomes are difficult to evaluate precisely, as those alterations are 
occurring at submucosal level. Hence evaluation of clinical symptoms may not 
precise to evaluate the efficacy of medical therapy. In order to evaluate this condition 
better, monitoring the improvement at submucosal level is mandatory. Currently an 
innovative imaging modality, USG provides visualisation of changes at submucosal 
level at real time basis. 
USG imaging is considered to be a “real- time” imaging, wherein the 
reflected echoes are processed at a rapid frame rate to allow simultaneous perception 
of physiologic motion. The echogenecity of a tissue primarily relates to its 
‘stiffness’, the chief source of which is collagen, the content and arrangement of 
collagen within tissue. It also provide both qualitative and quantitative assessment of 
mucosal tissue. 
Thus the present study is indent to evaluate and compare the effectiveness of 
oral pentoxifylline with respect to combined intralesional injection of dexamethasone 
and hyaluronidase in OSMF patients using USG by measuring the changes in 
submucosal thickness and echogenisity before and after treatment in both the groups. 
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To best of our knowledge, this is the first study based on USG to evaluate the 
efficacy of pentoxifylline therapy in OSMF patients. 
In our study we administered 400mg of pentoxifylline thrice daily for a 
period of three months for patients in group A and 1ml of dexamethasone with 1500 
I.U of hyaluronidase in 0.5ml of local anesthesia biweekly for 6 weeks in group B 
patients. The recommended adult dosage of oral pentoxifylline is 400mg three times 
a day with meals for hemorrheologic indications, which is also recommended for 
most other clinical applications
80
. Only few clinical trials regarding the effectiveness 
of pentoxifylline in the management of OSMF, has been reported till date. The study 
conducted by Anjum aara et al used a dosage of 400mg of pentoxifylline two times 
to three times  a day for a period of 3 months
45
. The outcome of this study showed 
significant clinical improvement with minimal side effects. Therefore we decided to 
use thrice daily regimen for three months. 
A total of 30 patients with age ranging from 23- 54 years, with the mean age 
being 35.4 years in group A and 32.8 years in group B, were included in the study . 
The age distribution in this study is correlated with that stated by other authors
97
. Out 
of 30 subjects enrolled in the study 24 were males and 6 were females. A male 
predilection was observed. All the 30 patients in the study had a pan chewing habit. 
In another study from Chennai, out of 185 patients, only one patient did not have a 
history of areca nut chewing
19
. 
The symptoms commonly reported include burning sensation of mouth, 
reduced mouth opening, decreased salivation and altered taste perception. Burning 
sensation may be attributed to an atrophic epithelium, but currently the morphologic 
evidence of increased cell death was failed to be noticed in OSMF epithelium when 
compared to site adjacent healthy oral mucosa
68
. Stomatitis resulting from nutritional 
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deficiency may also lead to burning sensation. Several investigators have reported 
nutritional deficiencies such as anemia, vitamin, iron, and protein deficiencies in 
patients with OSMF
7
. The burning sensation may also be aggravated by the 
xerostomia that is seen in the later stages of the disease. 
Burning sensation of the mouth and a reduction in mouth opening was 
present in all the 30 patients enrolled in the study. There was a complete reduction in 
the burning sensation in all the 15 patients in group A and 13 patients in group B. 
Two of the patient in group B reported with mild persistence of burning sensation 
even at the end of the treatment. Both the groups showed highly significant 
(p<0.001) reduction in burning sensation. The improvement in regional blood flow 
by pentoxifylline could explain the significant reduction in burning sensation 
observed in our study. Treatment of OSMF with intralesional injections of 
corticosteroids (dexamethasone or triamcinolone acetonide), hyaluronidase and 
chymotrypsin has been reported to reduce burning sensation in 82% - 94% of OSMF 
patients
42
. All the patients in our study treated with pentoxifylline showed highly 
significant reduction in burning sensation. 
Restricted mouth opening is the most debilitating feature associated with 
OSMF. As the disease progresses, thick fibrous bands appear in the submucosal layer 
of the oral soft tissues. This progressive oral fibrosis is usually bilateral and causes 
an increasing restriction of mouth opening.
 
The mouth opening ranged from 16-
36mm was observed in our study. In a study conducted in Chennai, majority (76%) 
of the patients had a mouth opening between 20-45mm. All the 30 patients in the 
study showed significant increase in the degree of mouth opening. However 
pentoxifylline showed slightly higher percentage than (17.96%) than dexamethasone 
group (10.04%). 
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No known treatment for OSMF can restore the mouth opening to normal, 
although some medical and surgical interventions may result in improvement. 
Significant alleviation in mouth opening by pentoxifylline might be due to combined 
physiological action of anti-inflammatory, fibrinolytic, immunomodulating and 
rheologic modifying property of the drug  altogether. 
Ultrasonogarphic evaluation of submucosal thickness and echogenicity of 
buccal mucosa reflect degree of deposition of collagen fibre and stiffness of mucosa. 
Hence measuring this parameter will be helpful in screening, assessing the extension 
of the fibrosis and the effectiveness of treatment outcome. And also noted that 30% 
improvement in submucoal thickness had been noticed in group A and only 17 % 
improvement was noticed in group B. similarly mouth opening also showed 
marginally better improvement in group A (17.96 %) and group B (10.04% ). 
Eventhough, both the groups are highly significant, group A showed marginally 
better changes in all parameters compared to group B.  
In study conducted by Anjum Aara et al
45
, dexamethasone group showed 
better result compared to pentoxifylline group. But in their study, all parameters were 
of clinical like burning sensation, mouth opening and cheek flexibility. And also they 
prescribed twice daily dose of pentoxifylline for the first four week, which may have 
influenced the result of their study.  
ADVERSE EFFECTS: 
Most of the side effects caused by pentoxifylline involve the gastrointestinal 
system and central nervous system. In our study pentoxifylline was generally well 
tolerated by almost all of the patients. Mild gastric irritation was experienced by two 
patient and Giddiniess in another patient but neither of the patients had reason to 
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discontinue the therapy. Patient with gastric irritation was managed by advised to 
take the medication with meals. In the other reported study where Pentoxifylline has 
been used in 15 OSMF, one patient experienced continued gastric irritation 
warranting cessation of therapy. No other reportable side effects or complications 
were recorded from any of the other patients in the same study. 
LIMITATION OF THE STUDY: 
The present study was conducted on 30 patients, 15 in each group. A larger 
sample size would have allowed for better observation and analysis of the disease 
findings and the effects of the intervention. Duration of pan chewing with severity of 
OSMF was not considered, which may be helpful in assessing the implication of 
drug in treatment outcome. The study parameters were recorded only during the 
duration of the treatment, which were 3 months in group A and 6 weeks in group B. 
There was no follow up after cessation of active medication. Post-treatment follow 
up would have allowed for documentation of sustained effect of the intervention and 
possible relapse.  
. USG evaluation was done only before and after the end of the treatment, 
during the course of treatment was not performed. It may be helpful in evaluating 
initial appearance of improvement after medication. And also dexterous skill and 
experience is required for manipulation of ultrasonography and values may change 
from observer to observer as there is no definitive landmark to define. Hence we took 
multiples values and average of which is tabulated and analysed. We used extraoral 
transducer for USG evaluation because of non availability of intraoral transducer, 
which may be helpful in further detailed analysis of oral submucosa including 
vascularity. 
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SUMMARY AND CONCLUSION 
Oral submucous fibrosis is a common pre-malignant condition affecting the 
oral mucosa with more prevalence among Indian population. Various treatment 
modalities have been elucidated in order to alleviate the symptoms associated with 
OSMF. Currently oral pentoxifylline has been  proved  to have beneficial result in 
treating OSMF because of its anti-inflammatory, fibrinolytic ,immunomodulatory 
and rheologic modifying property. The present study was done to evaluate the 
effectiveness of oral pentoxifylline in the management of OSMF and the efficacy of 
USG in evaluating that effectiveness, as it provides both qualitative and quantitative 
assessment of oral mucosa.  
Several categories of drugs have been used in the treatment of OSMF but 
their effectiveness leaves much to be desired and no treatment regimen has afforded 
definitive cure. While  Oral administration limits the concentration of drugs in 
lesional tissue and increases the potential for side effects, the Intralesional injections 
are associated with significant mechanical injury and non compliance on the patient’s 
part because of the accompanying discomfort and pain. 
 In this study both pentoxifylline and dexamethasone group showed 
significant improvement in mouth opening, reduction in burning sensation. 
Pentoxifylline appears to be well tolerated. Only 2 patients experienced side effects, 
but neither had reason to discontinue the therapy. Hence pentoxifylline can be a good 
alternative in the management of OSMF for whom intralesional steroids or 
hyaluronidase are contraindicated, for those who cannot make frequent visit and to 
avoid pain due to injection. And most importantly pentoxifylline is cost effective and 
more compliant to the patient. 
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Furthermore, qualitative and quantitative assessment of  pentoxifylline 
effectiveness in treating OSMF was  assessed by  USG  showed marked changes in  
submucosal thickness and echogenicity in lieu with the  clinical improvement. Hence 
USG can be considered as a valuable tool in assessing the severity, extension, disease 
progression and treatment outcome objectively and efficiently. But further 
descriptive study is required to substantiate the sensitivity of USG in OSMF 
evaluation, in all respects.  
However the present study involved a small sample size, thus the results of 
our study need to be confirmed in a larger population of OSMF patients with a longer 
period of follow up. Also further study is required to assess the effectiveness of 
pentoxifylline on the basis of extent of efficacy in different age groups, at various 
stages of OSMF, and duration of habit associated with OSMF. 
 The future directions in the management of OSMF should thus include 
development of treatment regimens that combine different drugs or uses sequential 
therapy. Though the individual treatment response to pentoxifylline showed 
significant improvement, additional studies are required to further establish the role 
of pentoxifylline in observed therapeutic effects. Quality randomized, controlled 
trials and increasing the global awareness of the disease for greater inflow of 
research data and research on possible treatment approaches is the need of the hour. 
Lastly, OSMF is a preventable disease; simple public health awareness of the 
harmful effects of chewing areca and other products could go a long way in 
combating this debilitating disease. 
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  INFORMED CONSENT FORM  
STUDY TITLE: 
ULTRASONOGRAPHIC EVALUATION OF ORAL SUBMUCOUS FIBROSIS 
TREATED WITH ORAL PENTOXIFYLLINE AND INTRALESIONAL 
DEXAMETHASONE WITH  HYALURONIDASE 
Name:                                       Age / Sex:                     O.P.No: 
 
Address:               Serial No:  
Tel. no: 
 
I, ___________________________________________________age____years 
Exercising my free power of choice, hereby give my consent to be included as a 
participant in the study “Ultrasonographic Evaluation of Oral Submucous Fibrosis 
treated with Pentoxifylline and Intralesional Dexamethasone with 
Hyaluronidase”. 
 I agree to the following: 
 I have been informed to my satisfaction about the purpose of the study and 
study procedures including investigations to monitor and safeguard my body 
function. 
 I agree to cooperate fully and to inform my doctor immediately if I suffer any 
unusual symptom. 
 I have informed the doctor about all medications I have taken in the recent 
past and those I am currently taking and other systemic illness that I have. 
 I agree to report to the doctor for a regular follow-up as and when required for 
the research. 
 I hereby give permission to use my medical records for research purpose. I am 
told that the investigating doctor and institution will keep my identity 
confidential. 
 
Name of the patient               Signature / Thumb impression  
 
Name of the investigator               Signature    
Date 
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INFORMATION SHEET 
 
 We are conducting an Ultrasonographic Evaluation of Oral Submucous 
Fibrosis treated with Oral Pentoxifylline and Intralesional 
Dexamethasone with Hyaluronidase” among patients attending TNGDCH, 
Chennai and for that study we are selecting patients. 
 The purpose of the study is to evaluate the therapeutic benefit of oral 
Pentoxifylline in oral submucous fibrosis patients using ultrasonography.. 
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
Name of the investigator                                              Name of the patient  
 
Signature of investigator                                                   Signature of patient  
 
 
Date:         
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MuhŒ¢á jftš jhŸ 
thŒ ïW¡F nehŒ¡F bg‹lh¡ÎãÈ‹ kh¤âiu k‰W« 
bl¡[hbkjnrh‹ AaÿnuhÅnl° ïil¤âR á»¢irÆ‹ M‰wiy 
ÛbahÈ bfh©L brŒí« gF¤jhŒî F¿¤J MuhŒ¢á  brŒí« bghU£L 
jÄœehL muR gš kU¤Jt¡ fšÿÆ k‰W« kU¤Jtkid¡F tU« 
nehahËfis eh¤fŸ nj®î brŒ»nwh«. 
ïªj MuhŒ¢áÆš g¤nf‰F« nehahËfË‹ Çgu¤fŸ MŒî 
Koî« tiu ïufáakhf it¡f¥gL«. MuhŒ¢áÆ‹ Koî g‰¿a ghâ¥òfŸ 
mšyJ btËpLfŸ ahUila jÅ¥g£l Çtu¤fS« g»®ªJ 
bfhŸs¥glkh£lhJ. 
ïªj MuhŒ¢áÆš g¤nf‰F« c¤fŸ Koî j‹Å¢irahdJ. ïªj 
MuhŒ¢áÆš g¤nf‰F« Ú¤fŸ vªjneu¤âY« Çy»¡ bfhŸtj‰F« 
c¤fS¡F thŒ¥ò cŸsJ. c‡¡Ë‹ ïªj Ô®khd¤âdhš c¤fS¡F 
ï«kU¤JtkidÆš tH¤f¥gL« ga‹fËš v›Çj kh‰wK« ïU¡fhJ.  
ïªj áw¥ò MŒÇ‹ KoîfŸ, ïªj MŒÇ‹ KoÇš mšyJ 
MŒÇ‹nghJ V‰gL« vâ®kiwahd Çisîfis mªnehahËfË‹ 
ey‹fUânah mšyJ á»¢iraË¡F« bghU£nlh nehahË¡F 
bjÇÉ¡f¥gL«. 
 
MŒthsÆ‹ ifbah¥g«                  g¤nf‰ghs® ifbah¥g« 
njâ : 
ïl« : 
Appendix 
 
Ra x¥òjš got« 
MŒî brŒa¥gL« jiy¥ò  
thŒ ïW¡F nehŒ¡F bg‹lh¡ÎãÈ‹ kh¤âiu k‰W« 
bl¡[hbkjnrh‹ AaÿnuhÅnl° ïil¤âR á»¢irÆ‹ M‰wiy 
ÛbahÈ bfh©L brŒí« gF¤jhŒî F¿¤J MuhŒ¢á  
 
MuhŒ¢á Ãiya« : muR gš kU¤Jt¡ fšÿÆ 
br‹id - 600 003 
g¤F bgWgtÆ‹ bga® :  
g¤F bgWgtÆ‹ v© :  
g¤F bgWtÆ‹ ãwªj njâ : __________ / __________ /__________  
      njâ      khj«  tUl« 
ïªj MuhŒ¢á r«gªjkhf eh‹ nkny Tw¥g£l jftš got¤ij 
KGikahf go¤J¥ gh®¤nj‹ v‹W cWâ TW»nw‹.  
eh‹ ïJ bjhl®ghd mid¤J nfŸÇfS¡F« Ãiwthd gâšfŸ 
bgw¥g£nl‹. 
ïªj MŒÇ‹ vdJ g¤F j‹Å¢irahdJ v‹W« vªj neu¤âY« 
ïªj MŒÇš ïUªJ r£l cÆikfŸ ghâ¡f¥glhkš Çy»¡ bfhŸs 
r«kâ¡»nw‹. 
kU¤Jt MŒî mâfhÆfŸ, vdJ á»¢ir bjhl®ghd gântLfis 
gh®itÆlî« vªj neu¤âY«, MŒÇš ïUªJ eh‹ Çy»dhY« 
gh®itÆl r«kâ¡»nw‹. vdJ milahs F¿¥òfŸ _‹whtJ egU¡F 
bjÆÇ¡f¥glkh£lhJ v‹W òÆªJ bfh©nl‹. 
ïªj MŒî m¿¡iffis ga‹gL¤jî«, btËÆlî«, eh‹ 
r«kâ¡»nw‹. MŒths® vdJ kU¤Jt¡ F¿¥òfis btËÆl jilahf 
ïU¡fkh£nl‹ vd c©ikahf r«kâ¡»nw‹. 
 
g¤nf‰gtÆ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………….. 
f£ilÇuš nuif 
g¤nf‰gtÆ‹ bga® k‰W« Çyhr« …………………………………………… 
MŒthsÆ‹ ifbah¥g« ……………….. ïl«…………….. njâ…………….. 
MŒthsÆ‹ bga® ………………………………………… 
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                DEPARTMENT OF ORAL MEDICINE AND RADIOLOGY     
      TAMIL NADU GOVT. DENTAL COLLEGE & HOSPITAL, CHENNAI -3   
CASE PROFOMA 
ULTRASONOGRAPHIC EVALUATION OF ORAL SUBMUCOUS FIBROSIS TREATED WITH ORAL 
PENTOXIFYLLINE AND INTRALESIONAL DEXAMETHASONE WITH HYALURONIDASE 
Date:                                                                            Serial no: 
Name:                                                                          O.P No: 
Age/Sex: 
Address: 
 
Phone no: 
Occupation:                                                                Income: 
Centre :   1.   Department Of  oral medicine and radiology,     
         Tamil Nadu Govt Dental College & Hospital, Chennai -3   
     2.  Bernard Institute of Radiology(BIR),  
                       Rajiv Gandhi Government General Hospital , chennai                                                                                                
Presenting complaint with duration: 
 
 
Past medical history: 
 
 
Past dental history: 
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Personal history: 
Marital status: 
 
Family history: 
 
A) Smoking habit: 
 Material used: 
 Frequency      : 
 Duration of the habit: 
 
B) Chewing habit: 
 Material used: 
 Frequency      : 
 Duration of the habit: 
 
C) Other habits (alcohol, snuff): 
 
 
 
 
CLINICAL EXAMINATION 
Extraoral Examination: 
 
 
Intraoral examination: 
 Mouth opening (Inter incisal distance): 
 
 Labial and buccal mucosa: 
 
 Hard and soft palate, Uvula: 
 
 Tongue 
 
 Floor of the mouth: 
 
 Retromolar trigone: 
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Clinical diagnosis: (with grading) 
          
 
 
Investigations: 
 
1) Laboratory investigations: 
 
A) Blood: 
Total WBC count:                                          Erythrocyte sedimentation rate: 
Differential count:                                        Bleeding time: 
Haemoglobin %:                                             Clotting time: 
Peripheral smear: 
 
 
B) Urine: 
Glucose: 
Albumin: 
 
OTHERS INVESTIGATION: 
 
 
 
 Final diagnosis: 
 
 
 
       Treatment plan: 
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CLINICAL AND ULTRASONOGRAPHIC ASSESMENT FORM 
 
         NAME:                                 AGE /SEX:                                            OP. NO:                    Serial NO. : 
 
         DIAGNOSIS :                                                        GFROUP ASSIGNED: 
 
         CLINICAL PARAMETERS: 
         Burning Sensation ( VISUAL ANALOG SCALE): 
 
BEFORE TREATMENT (VAS score) AFTER TREATMENT(VAS score) 
  
 
         Mouth Opening : (Interincisal Distance) 
BEFORE TREATMENT AFTER TREATMENT 
RIGHT LEFT RIGHT LEFT 
…………….mm …………….mm …………….mm …………….mm 
 
         USG EVALUATION : 
         Submucosal Thickness 
BEFORE TREATMENT (mm) AFTER TREATMENT(mm) 
RIGHT LEFT RIGHT LEFT 
    
 
         Echogenicity: (hyperechoic/hypoechoic) score 1/2 
BEFORE TREATMENT(score) AFTER TREATMENT(score) 
RIGHT LEFT RIGHT LEFT 
    
 
 
    SIGANATURE OF  PG STUDENT                                        SIGNATURE OF GUIDE 
                
                DATE : 
[Type the document title] 
 
 
 
TRIPARTITE AGREEMENT 
This agreement hereinafter the “Agreement” is entered into on this 
day……………. between the Tamil Nadu Government Dental College and Hospital 
represented by its Principal having address at Tamil Nadu Government  Dental 
College and Hospital, Chennai- 600 003, (hereinafter referred to as, ‘the college’) 
 And  
  Dr. S. JAYACHANDRAN, M.D.S., Ph.D., aged 50 years working as 
Professor in Department of Oral medicine and Radiology at the college, having 
residence address at A.M -16, TNHB quarters, tod hunter nagar, saidapet,Chennai – 
15.(herein after referred to as the ‘Principal Investigator’)  
And 
  Dr. SURESH KUMAR M, aged 30 years currently studying as final year 
Postgraduate student in the Department of Oral Medicine and Radiology, Tamil 
Nadu Government Dental College and Hospital, Chennai -3 ( hereafter referred to as 
the ‘PG and co- investigator’) residing at no.166, Kottai Allah Kovil Street, Packiyam 
Nagar, Patukkottai-614601 
Whereas the ‘PG student as part of her curriculum undertakes to research on 
“Ultrasonographic Evaluation of Oral Submucous Fibrosis treated with Oral 
Pentoxifylline and Intralesional Dexamethasone with Hyaluronidase” for which 
purpose the Principal investigator shall act as Principal investigator and the College 
shall provide the requisite infrastructure based on availability and also provide facility 
to the PG student as to the extent possible as a Co-investigator 
 
Whereas the parties, by this agreement have mutually agreed to the various 
issues including in particular the copyright and confidentiality issues that arise in this 
regard 
 
Now this agreement witnessed as follows : 
1. The parties agree that all the Research material and ownership therein shall 
become the vested right of the college, including in particular all the copyright 
in the literature including the study, research and all other related papers. 
2. To the extent that the college has legal right to do go, shall grant to licence or 
assign the copyright so vested with it for medical and/or commercial usage of 
interested persons/entities subject to a reasonable terms/conditions including 
royalty as deemed by the college. 
3. The Royalty so received by the college shall be shared equally by all the three 
parties. 
[Type the document title] 
 
 
 
4. The PG/Research student and PG/Principal Investigator shall under no 
circumstances deal with the copyright, Confidential information and know-
how-generated during the course of research/study in any manner whatsoever, 
while shall sole west with the college. 
5. The PG student and Principal Investigator undertake not to divulge (or) cause 
to be divulged any of the confidential information or, know-how to anyone in 
any manner whatsoever and for any purpose without the express written 
consent of the college. 
6. All expenses pertaining to the research shall be decided upon by the principal 
investigator/Co-investigator or borne sole by the PG student.(co-investigator) 
7. The college shall provide all infrastructure and access facilities within and in 
other institutes to the extent possible. This includes patient interactions, 
introductory letters, recommendation letters and such other acts required in 
this regard. 
8. The Principal Investigator shall suitably guide the Student Research right from 
selection of the Research Topic and Area till its completion. However the 
selection and conduct of research, topic and area research by the Student 
Researcher under guidance from the Principal Investigator shall be subject to 
the prior approval, recommendations and comments of the Ethical Committee 
of the College constituted for this purpose. 
9. It is agreed that as regards other aspects not covered under this agreement, but 
which pertain to the research undertaken by the PG student, under guidance 
from the Principal Investigator, the decision of the College shall be binding 
and final. 
10. If any dispute arises as to the matters related or connected to this agreement 
herein, it shall be referred to arbitration in accordance with the provisions of 
the Arbitration and Conciliation Act, 1996. 
 
In witness where of the parties herein above mentioned have on this the day 
month and year herein above mentioned set their hands to this agreement in 
the presence of the following two witnesses. 
 
College represented by its Principal                               PG Student  
  
 
Witnesses                                                                          Student Guide 
  1. 
 
  2. 
 
